CONFIDENTIAL Page 1 of 96   
 
 
 
A Phase II, Multi-center, Two-Part (Par t 1: Randomized, Double-Blind, Placebo- 
Controlled with Leronlimab 700mg and placebo; and Part 2: Open-label, Single Arm with 
Leronlimab 350mg), Three-Arm, Dose-Ranging Study of the Safety and Efficacy of 
Leronlimab (PRO 140) in Adult Patients with Nonalcoholic Steatohepatitis (NASH) 
  
 
 
Protocol Number: CDI-NASH-01  
Final Version: 7.0 
Date: 14-Jun-2021  
 
Sponsor:  
CytoDyn, Inc. 
[ADDRESS_1072942] 
Vancouver, Washington [ZIP_CODE] 
(360)  980-8524-Work  
(360)  980-8549-Fax  
www.cytodyn.com 
 
  
 
  
 
  
 
  
 
 
Confidentiality Statement 
 
This document is a confidential communication of CytoDyn,  Inc. It is provided for the conduct of a clinical 
research study. The information contained in this docume nt is confidential and, except to the extent necessary 
to obtain informed consent or IEC/IRB approval, ca nnot be disclosed unless required by [CONTACT_780580]. Persons to whom any portion of the contents of this document is disclosed must be informed that 
the information is confidential and may not be further disclosed by [CONTACT_476]. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 2 of 96  
  
PROTOCOL APPROVAL PAGE 
 
 
Protocol Number: CDI-NASH-01 
Final Version: 7.0 
Date: 14-Jun-[ADDRESS_1072943] icable regulatory guidelines and statutes. 
 
 
PROTOCOL APPROVAL FOR USE 
 
 
 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 3 of 96  
  
INVESTIGATOR’S SIGNATURE [CONTACT_768705]: CDI-NASH-01 
Final Version: 7.0 
Date: 14-Jun-[ADDRESS_1072944] of this clini cal trial. I also agree to comply with  US Food and Drug Administration (FDA) 
regulations and Investigational Review  Board/Institutional Ethics (IRB/IEC) requirements for testing on human 
subjects. I agree to ensure that the requirements for obtaining informed consent are met. 
 
 
  
 
  
 
Principal Investigator’s Signature  [CONTACT_780610] r   
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1072945] 
Vancouver, Washington [ZIP_CODE] 
(360)  980-8524-Work  
(360)  980-8549-Fax  
www.cytodyn.com 
 
  
 
   
 
 
 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 7 of 96  
  
mg dose) will be weekly administered subcutaneously (SC) by a licensed healthcare professional at the clinic 
sites. 
 Part 1 : randomized, double-blind, placebo-controlled, two-arm (up to 60 subjects) 
 Leronlimab (PRO 140 700 mg) or Placebo SC weekly injection for 13 weeks 
 Part 2 : non-randomized, open-label, single-arm (up to 30 subjects) 
 Leronlimab (PRO 140 350 mg) SC weekly injection for 13 weeks 
This study consists of screening,  treatment, and follow-up periods. 
Screening Period (Up to 4 weeks): 
Screening assessments will commence after obtaining signed Informed Consent Form (ICF), and review of 
medical history, demographic information, baseline di sease characteristics, eligibi lity evaluation, physical 
examination, vital signs, height and weight, prior an d concomitant medications, electrocardiogram (ECG), 
Liver MRI, FibroScan (or equivalent non-invasive im aging test), FibroTest, routine serum biochemistry 
including liver function test, hematology, HIV and hepatitis serology panel, urinalysis, serum pregnancy (if applicable). These assessments must be conducted within [ADDRESS_1072946] treatment visit. Subjects who fail to meet eligibility criteria will be considered screen failures and exit the study without any further 
evaluations. 
Treatment Period (Up to 14 Weeks): 
In the Part 1 of the study, subjects who meet all eligib ility criteria, as per data gathered from Screening Visit, 
will be randomized 1:1 to one of the two study arms to receive Leronlimab 700 mg (Group A), or placebo 
(Group B) during the treatment period. 
 PRO 140 (700mg) SC weekly injection (Group A) 
 Placebo (0 mg) SC weekly injection (Group B) 
Study treatments for each group (Leronlimab 700 mg or placebo) will be subcutan eously administered every 
week by a licensed healthcare profes sional at the study site for 13 weeks. The End of Treatment (EOT) visit 
(or early withdrawal visit in case of patients withdr awn prematurely from the stud y) will happen [ADDRESS_1072947] study treatment. 
In the non-randomized, single-arm, op en-label phase (Part 2) of the study, leronlimab (PRO 140 350 mg 
dose) will be weekly administered subcutaneously (SC)  by a licensed healthcare professional at the clinic 
sites for 13 weeks. 
Follow-Up Period: 
A Follow-Up visit will be conducted 28 (± 3) days after the End of Treatment (EOT) or Early Termination 
(ET) Visit. 
Duration of Treatment: 
 Screening Period: Up to 4 weeks 
 Treatment Period: Up to 14 weeks 
 Follow-Up Period: Up to 4 weeks after End of Treatment (EOT) or Early Termination (ET) Visit 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1072948] of Abbreviations ......................................................................................................... ............ 19 
1 INTRODUCTION AND  BACKGR OUND .......................................................................... 23 
1.1 Statement of Intent ........................................................................................................... .... 23 
1.2 Background of the Disease .................................................................................................. 23  
Inflammatory response in nonalcoho lic steatohepatitis (NASH) ......................................... 23 
1.3 Study Treatment  ................................................................................................................... 24 
Leronlimab (PRO 140) ........................................................................................................ 24 
1.4 Pre-Clinical Studies of Leronlimab (PRO 140) ................................................................... 24 
Non-Clinical Studies with Leronlimab (PRO 140) on NASH ............................................. 25 
1.5 Clinical Studies with Leronlimab (PRO 140) ...................................................................... 25 
PRO 140 1101 Study ........................................................................................................... 25 
PRO 140 1102 Study ........................................................................................................... 26 
PRO 140 1103 Study ........................................................................................................... 26 
PRO 140 1302 Study ........................................................................................................... 26 
PRO 140 2301 Study ........................................................................................................... 26 
PRO 140 2101 Study ........................................................................................................... 27 
PRO 140_CD01 Study ......................................................................................................... 27  
PRO 140_CD01 Extension Study ........................................................................................ 28 
PRO 140_CD02 Study ......................................................................................................... 29  
PRO 140_CD06 Study ......................................................................................................... 30  
PRO 140_CD02 Extension Study ........................................................................................ 30 PRO 140_CD03 HIV Study ................................................................................................. 30 
PRO 140_CD03 HIV Extension Study ................................................................................ 31 
CD07_TNBC Study ............................................................................................................. 3 1 
CD08_mCRC Study ............................................................................................................ 31  
1.6 Dose Section Rationale ........................................................................................................ 34 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 13 of 96  
 1.7 Risks / Benefits Assessment ............................................................................................... 36 
Risks/Discomfort to Subjects and Pr ecautions to Minimize Risk ....................................... 36 
Intended Benefit for Subjects .............................................................................................. 37  
2 STUDY OBJECTIVES ......................................................................................................... 38 
2.1 Primary Objective ............................................................................................................. .. 38 
2.2 Secondary Objective: ..........................................................................................................  38 
3 STUDY DESIGN .................................................................................................................. . 39 
3.1 Study Centers ................................................................................................................. ..... 39 
3.2 Study Popu lation .............................................................................................................. ... 39 
3.3 Eligibility Criteria .......................................................................................................... ..... 41 
Inclusion Criteria ............................................................................................................ .... 41 
Exclusion Criteria ............................................................................................................ ... 42 
4 STUDY SCHEDULE ............................................................................................................ 45 
4.1 Screening Period .............................................................................................................. ... 50 
Screening Visit ............................................................................................................... .... 50 
4.2 Treatment Period .............................................................................................................. .. 51 
Treatment Visit 1 (T1) ........................................................................................................  52 
Treatment Visit 2 (T2) to Treatment Visit 13 (T13) ........................................................... 53 
End of Treatment (EOT) Visit ............................................................................................ 54 
Early Termination (ET) Visit .............................................................................................. [ADDRESS_1072949] .......................................................................................................  61 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 14 of 96  
 Leronlimab (PRO 140) ........................................................................................................ 61 
Placebo 61 
6.2 Leronlimab (PRO 140) - Packaging and Labeling .............................................................. 62 
6.3 Leronlimab (PRO 140) - Storage and Handling .................................................................. [ADDRESS_1072950] Accountability  ................................................................................. 65 
7 DESCRIPTION OF PROTOCOL ASSESSMENTS AND PROCEDURES ..................... 66 
7.1 Informed Consent .............................................................................................................. .. 66 
7.2 Assessment of Eligibility .....................................................................................................  66 
Re-screening .................................................................................................................. ...... 66 
7.3 Demographic Informatio n and Baseline Disease Characteristics ........................................ 66 
7.4 Medical History ............................................................................................................... .... 67 
7.5 Concomitant Medication ...................................................................................................... 6 8 
Permitted Medications .........................................................................................................  68 
Prohibited Medications ........................................................................................................  68 
7.6 Vital Signs, Height and Weight ........................................................................................... 69 
7.7 Physical Examination ..........................................................................................................  69 
7.8 Electrocardiogram (ECG) .................................................................................................... [ADDRESS_1072951]-Injection Evaluatio n and Injection Site Reaction Assessment ..................................... 73 
7.12 Pain Severity Assessment .................................................................................................... 7 3 
7.13 Fibroscan ..................................................................................................................... ......... 74 
7.14 Liver MRI (M ultiScan ) ........................................................................................................ 74 
8 STATISTICAL  ANALYSIS .................................................................................................. 75 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 15 of 96  
 8.1 Treatment Groups  .............................................................................................................. .. 75 
8.2 Study Outcome Measures  ..................................................................................................... 75 
Primary Efficacy Outcome Measure .................................................................................... 75 
Secondary Efficacy Outcome Measures: ............................................................................. [ADDRESS_1072952] Di spositio n ........................................................................................................... ... 78 
Demographic and Baseline Disease Characteristics ............................................................ 78 Study Analyses ................................................................................................................ .... 78 
Efficacy Analysis ............................................................................................................. .... 
78 
Safety Analyses ............................................................................................................... .... 78 
9 ADVERSE EVENTS (DEFINITIONS AND REPORTING) .............................................. 80 
9.1 Adverse event (AE) ............................................................................................................ . [ADDRESS_1072953] on Study Treatment .................................................................................................. 80  
CTCAE Grade (Intensity) Assessment  ................................................................................. 81 
Causality Assessment ..........................................................................................................  81 
Treatment Given as a Result of the Event ........................................................................... 82 
Outcome Assessment ........................................................................................................... 82 
Injection-site reactions ...................................................................................................... ... 82 
9.3 Serious Adverse Events ....................................................................................................... 82 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1072954] ACCESS TO SOURCE DATA/DOCUMENTATION ........................................ 85 
11 QUALITY CONTROL AND Q UALITY ASSU RANCE .................................................... 86 
11.1 Monitoring Requirements .................................................................................................... 86  
11.2 Acceptability of Case Report Forms (CRFs) ....................................................................... [ADDRESS_1072955]/Independ ent Ethics Committee (IRB/IEC) .............................. 89 
12.2 Investigator’s Re sponsibilities ............................................................................................. [ADDRESS_1072956] KEEPI[INVESTIGATOR_1645] ................................................................. 91 
13.1 Recording and Collection of Data ....................................................................................... 91 
13.2 Clinical Data Management .................................................................................................. 91 
13.3 Archiving ..................................................................................................................... ........ 92 
14 PUBLICATION  PLAN .......................................................................................................... 93 
15 REFERENCES .................................................................................................................... ... 94 
16 APPENDIX ...................................................................................................................... ....... 95 
16.1 Appendix 1: Acceptable Methods of Contraception ........................................................... 95 
16.2 Appendix 2: Common Terminology Criteria for Adverse Events v5.0 ............................... 96 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1072957] OF TABLES 
Table 1-1: List of Completed Clinical Studies with Leronlimab (PRO 140) ........................... 32 
Table 1-2: List of Ongoing Clinical St udies with Leronlimab (PRO 140) ............................... 33 
Table 4-1: Treat ment Gr oups ...................................................................................................  45 
Table 4-2: Schedule of Assessments ........................................................................................ 47 
Table 6-1: Treatment Administration Summary ...................................................................... 61 
Table 6-2: Part 1: Investigational Produc t - Leronlimab (PRO  140) or Placebo ...................... 62 
Table 6-3: Part 2: Investiga tional Product - Le ronlimab (PRO 140) ........................................ 62 
Table 6-4: Leronlimab (PRO 140) Dose Modification and Mana gement for Injection Site 
Reactions ................................................................................................................. 65 
Table 7-1: Central Lab Parameters ........................................................................................... 7 2 
Table 9-1: CTCAE v5.0 General Guidelines ........................................................................... 81 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1072958] OF FIGURES 
Figure 3-1: Study Design Schematic .......................................................................................... 4 0 
Figure 6-1: Investigationa l Product - Vial Label ........................................................................ 63 
Figure 6-2: Investigationa l Product - Kit Label .......................................................................... 63 
Figure 7-1: 11-Point Numeric Pain Rating Scale ....................................................................... 73 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1072959] Aspartate Aminotransferase 
BUN Blood Urea Nitrogen 
BMI Body Mass Index 
BLM Baseline Measurement 
CAP Controlled Attenuation Parameter 
CBC Complete Blood Count 
CBR Clinical Benefit Rate 
CCL5 C-C Chemokine Ligand Type-5 (RANTES) 
CCR5 C-C Chemokine Receptor Type-[ADDRESS_1072960] Research Organization 
Corrected T1 
Common Terminology Criteria for Adverse Events 
CVD Cardiovascular Disease 
D/M Dual/Mixed 
DILI Drug- Induced Liver Injury 
ECG Electrocardiogram 
ECL2 ExtraCellular Loop 2 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 20 of 96  
  
 
Abbreviation Term 
eCRF Electronic Case Report Form 
EASL European Association for the Study of the Liver 
eGFR Estimated Glomerular Filtration Rate 
EGFR Epi[INVESTIGATOR_780568] 
F1-F4 Fibrosis (Stage) 
FDA U.S. Food and Drug Administration 
Flu-Mist Influenza Vaccine 
FOCBP Females of Child-bearing Potential 
GCP Good Clinical Practice 
GGT Gamma- Glutamyltransferase 
GMP Good Manufacturing Practice 
GVHD Graft versus Host Disease 
HAV Hepatitis A Virus 
HbA1c Hemoglobin A1c 
HBsAg Hepatitis B Virus Surface Antigen HCC Hepatocellular Carcinoma 
HCV Hepatitis C Virus 
HEENT Head, Ears, Eyes, Nose, and Throat 
HEV Hepatitis E Virus HIPAA Health Insurance Portability and Accountability Act 
HIV- 1 Human Immunodeficiency Virus Type 1 
HSC Hepatic Stellate Cells 
IA Interim Analysis 
ICF Informed Consent Form 
ICH International Council for Harmonisation 
IEC Independent Ethics Committee 
IHC Immunohistochemistry assay 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1072961] to Follow-up 
mAb Monoclonal Antibody 
mCRC Metastatic Colorectal Cancer 
MedDRA Medical Dictionary for Regulatory Activities M/F 
MRI Male/Female Magnetic Resonance Imaging 
MSS Microsatellite Stable 
MTD Maximum Tolerated Dose mTNBC Metastatic Triple-Negative Breast Cancer NAFLD 
NASH Nonalcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis 
NOAEL No Observed Adverse Effect Level 
NCS Not Clinically Significant 
Nt N terminus 
OBT Optimized Background Therapy OELF Score Original European  Liver Fibrosis Panel Score 
ORR Overall Response Rate OTC Over the Counter PD Pharmacodynamics 
PDFF Proton derived fat fraction 
PI [INVESTIGATOR_780569] # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1072962] Upper Limit Normal 
US [LOCATION_002] 
USP [LOCATION_002] Pharmacopeia 
VEGF Vascular Endothelial Growth Factor 
VL Viral Load 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1072963] and reporting of  this study shall be conducted in  compliance with the protocol, 
International Council for Harmonisation/Good Clin ical Practice (ICH/GCP), and all appropriate 
regulatory requirements. Investigator(s) participating in this study will have documented training 
in GCP. Independent monitoring of the trial wi ll be accomplished utilizing a Contract Research 
Organization (CRO). 
 
1.2 BACKGROUND OF THE DISEASE 
Nonalcoholic steatohepatitis (NASH)  is a chronic liver disease characterized histologically by [CONTACT_780581] (hepatocellular ballooning) due to hepatic fat 
accumulation (steatosis) equal or superior to 5% of hepatocytes. NASH develops in the absence of 
excessive alcohol consumptio n but is linked to unhea lthy eating habits and lack of physical activity. 
It is often referred to as metabolic disease of the liver (Naga Chalasani, 2018). NASH can progress 
to high- burden conditions such as cirrhosis, end stage liver disease and Hepatocellular Carcinoma 
(HCC) (Manca Povsic, 2019). It is predicted that NASH will become the leading cause of liver 
transplantation by [ADDRESS_1072964] common form of chronic liver disease, 
affecting about one-quarter of the populat ion in the [LOCATION_002]. An estimated 3 -7% of the adult 
population develop NASH, of which approximately 15 -20% progress to advanced fibrosis or 
cirrhosis (Zobair M. Younossi, 2018 ). Despi[INVESTIGATOR_780570] , there are curre ntly no approved 
pharmacological therapi[INVESTIGATOR_110234]. Available therapi[INVESTIGATOR_780571], such as obesity, Type 2 Diabet es Mellitus (T2DM) and Cardiovascular Disease 
(CVD), while NASH management options focus on li festyle changes, based on diet and exercise, 
and control of the associated comorbidities. Lifest yle changes have demonstrat ed greatest benefit in 
improving steatosis and mild fibrosis; however, as patients with a dvanced fibrosis due to NASH are 
at a significantly higher risk of liver -related mortality, pharmacological treatments are urgently 
needed. 
Inflammatory response in nonalc oholic steatohepatitis (NASH) 
In NASH, liver homeostasis is impa ired due to an accumulation of t oxic lipi[INVESTIGATOR_805]. Certain gut bacteria- 
derived products can also penetrate in the live r, where they activate immune responses. This 
contributes to local inflammati on of hepatic tissue. This pat hological environment provokes 
hepatocytes damage and leads to a state called  ballooning. Steatosis, in flammation and ballooning 
are the three lesions that define NASH histologically. 
The inflammatory response to hepatocyte injury pl ays a key role in hepatic fibrogenesis and involves 
recruitment of inflammatory cells to the site of injury. Recruitment of extra-hepatic inflammatory 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 24 of 96  
  
cells to the site of hepatic injury is largely me diated by [CONTACT_780582]. Monocytes, Kupffer cells (KCs) and He patic Stellate Cells (H SCs) can express C-C 
chemokine receptor types 5 (CCR5 ) on their surface. Evidence impl icates CCR5 and their ligands 
including C-C chemokine ligand type 5 (CCL5) in th e pathogenesis of liver fibrosis following liver 
injury. 
It has also been shown that patie nts with chronic liver disease show  high levels of CCR5 and CCL5, 
thus showing the role of CCR5 an d its ligands in liver fibrosis. Numerous studies of NASH with 
other CCR5 agents have shown anti-inflammatory a nd anti-fibrotic effects (Lefebvre E, 2016). For 
that reason, CCR5 has become an attractive target for developi[INVESTIGATOR_780572] (Zobair 
M. Younossi, 2018). 
 
1.3 STUDY TREATMENT 
 
Leronlimab (PRO 140) 
Leronlimab (PRO 140) is a humanized IgG4,  Monoclonal Antibody (mAb) to the C-C chemokine 
receptor type 5 (CCR5), under development as a therapy for Human Immunodeficiency Virus 
(HIV) infection and other indications including triple negative  breast cancer, colorectal cancer and 
Graft versus Host Disease (GVHD). 
Leronlimab (PRO 140) has been administered intr avenously or subcutaneously to more than 750 
healthy and HIV-1 infected individuals in Phase I/II/III studies. The drug has been well tolerated 
following intravenous administration of single doses  of 0.5 to 10 mg/kg or up to 700 mg weekly 
doses as Subcutaneous (SC) injection. Overall,  more than [ADDRESS_1072965] been exposed to 
Leronlimab ( PRO 140) [ADDRESS_1072966] been exposed to Leronlimab ( PRO 140) 
[ADDRESS_1072967] exposure to PRO 140 525 mg 
and 700mg SC weekly dose is more than 2 years and 48 weeks, respectively. Considering its anti-CCR5 
activity and per the pre-clinical studies conducted, Leronlimab (PRO 140) is being developed as a 
potential therapy for liver fibrosis and inflammation conditions, including NASH. 
 
1.4 PRE-CLINICAL STUDIES OF LERONLIMAB (PRO 140) 
In vitro and in vivo preclinical studies have been conducte d to determine the pharmacokinetic, 
immunogenicity, and toxicity prof iles of Leronlimab (PRO 140) following Intravenous (IV) and 
SC administration. Several acute and chronic toxicity studies have been conducted to support the 
clinical development plan. 
Acute toxicity of Leronlimab (PRO 140) was evaluated in New Zealand rabbits, following IV 
administration of 5 or 15 mg/kg. Chronic toxicity was evaluated in cynomolgus monkeys following 
biweekly administration of IV doses up to 10 mg/ kg for six months and biw eekly administration of 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 25 of 96  
  
various SC doses up to 50 mg/kg for 24 weeks. The drug was genera lly well tolerated. Biweekly 
administration of IV doses up to 10 mg/kg for six months resulted in minimum to mild lymphoid 
hyperplasia in assorted lymph nodes and spleen, which was considered an expected immune 
response to a foreign protein. Biweekly admini stration of SC doses up to 50 mg/kg for 24 weeks 
resulted in minimum injection-s ite reactions (minimal, multifocal , mononuclear cell infiltrates in 
the subcutis), which were considered due to an inflammatory re sponse to the injected antigen. 
Monkeys tolerated treatment with Leronlimab (P RO 140) for 24 weeks without evidence of local 
or systemic toxicity. Leronlimab (PRO 140) caused no mortality, cageside observations, in-life 
injection-site observations, or gross pathologic findings. Chronic treatment with Leronlimab (PRO 
140) did not affect body weight, food consumption, hematology, clin ical chemistry or coagulation 
parameters. 
Both IV and SC administration resulted in elimin ation half-lives of approximately 200 hours, and 
overall exposure increased with increasing doses. Following SC administration of Leronlimab (PRO 
140) in monkeys, the maximal concentration (C max) was achieved within 56 hours and bioavailability 
for Leronlimab (PRO 140) after SC dosing was approximately 70%. 
Non-Clinical Studies with Leronlimab (PRO 140) on NASH 
An in vivo study was conducted to determine the anti-fibro tic activity of PRO [ADDRESS_1072968] CCR5 in mouse xenograft models of NASH (Study No.20127293). 
The objective of this study was to assess the effect of PRO 140 on NASH in mice when given by 
[CONTACT_780583]-weekly for 4 weeks. 
Reduction in liver fibrosis was observed when 2m g PRO 140 was administer ed via intraperitoneal 
injection twice weekly for 4 weeks 
 
1.5 CLINICAL STUDIES WITH LERONLIMAB (PRO 140) 
Current human experience with Leronlimab (PRO 140) consists of ten completed and six ongoing 
clinical trials, mostly on healthy subjects or HI V-1 positive subjects. These studies are summarized 
in Table 1-1 and Table 1-2 . In all clinical trials, the majority of Adverse Events (AEs) have been 
mild or moderate. No dose-limiti ng toxicities or patterns of drug-re lated toxicities were observed. 
PRO [ADDRESS_1072969]-in-human trial, PRO 140 1101, the drug was administered IV at 0.1, 0.5, 2.0, or 5.0 
mg/kg to healthy subjects a nd was generally well tolerated, non-immunogenic, and without 
clinically relevant toxicity. Treatment Emergent  Adverse Events (TEAEs) did not increase with 
rising PRO 140 dose levels. Seventy -five percent (75%) of subjects reported TEAEs, most of which 
were deemed unrelated to study treatment by [CONTACT_093]. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1072970] ug administration. PRO 140 derived from Chinese 
Hamster Ovary (CHO) cells and administered at  100 mg/mL was generall y well tolerated in 
healthy, normal volunteers. Overall, PRO [ADDRESS_1072971]® [ADDRESS_1072972]® [ADDRESS_1072973] perception of pain or discomfort related 
to site of drug administration. No anti-PRO 140 an tibodies were detected in any subjects in this 
study. There was a tendency of higher exposure associated with SC administration of PRO 140 at 350 mg in the abdomen and the thigh. A higher numbe r of AEs was associated with injections in 
the arm. Based on these observations, thigh and abdominal administration of PRO 140 were 
preferred over arm injection. 
PRO 140 1302 Study 
The initial proof-of-con cept study was a randomized, double-bli nd, placebo-controlled study in 
subjects with early-stage, asymptomatic HIV infection, only R5 HIV-1 detectable, and no 
antiretroviral therapy for 12 week s [Jacobson, 2008]. Subjects (n= 39) were randomized to receive 
a single IV injection of placebo or PRO 140 at doses of 0.5, 2, or 5 mg/kg. Subjects were monitored 
for antiviral effects, safety, and PRO 140 Pharmacokinetics (PK) for 58 days. 
PRO 140 demonstrated potent, rapid, prolonged, and dose-dependent antivira l activity. Intravenous 
PRO 140 was generally well tolerated. No drug-relate d serious events or dose-limiting toxicity was 
observed [Jacobson, 2008]. The most common adverse events (headache, lymphadenopathy, diarrhea, and fatigue) were observed at simi lar frequencies across the placebo and PRO [ADDRESS_1072974] on QTc intervals or other el ectrocardiographic parameters, 
and there were no remarkably laboratory findings. 
PRO 140 2301 Study 
PRO 140 2301 was a multi-center, randomized, double-bl ind, placebo-controlled, parallel group 
study in 30 male and female a dult subjects infected with HIV-1 [Jacobson, 2010]. Subjects were 
randomized to one of three groups (N=10/group), each receiving one of three treatments: (i) a single 
IV dose of 5 mg/kg by 30-minute IV infusion; (ii)  a single IV dose of 10 mg/kg by 30-minute IV 
infusion; (iii) a single placebo dose by 30-minute IV infusion. The objective of the study was to assess and characterize the Ph armacokinetics (PK) and Pharma codynamics (PD) of PRO 140 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 27 of 96  
  
administered by [CONTACT_16228], assess efficacy at a new dosage level, and safety and tolerability of 
single doses of PRO 140. 
All PRO 140-treated subjects had more than 10-fo ld reduction in viral lo ads [Jacobson, 2010]. Both 
the 5 mg/kg and 10 mg/kg doses have shown favor able tolerability and no dose-limiting toxicity 
has been observed. High levels of receptor oc cupancy (>85% reduction in the number of cells 
detected) were observed for 29 days after treatment with both 5 and 10 mg/kg doses. 
PRO 140 2101 Study 
A subcutaneous (SC) form of PRO 140 was tested  in HIV-infected subjects. The trial was a 
randomized, double-blind, placebo-controlled study in subjects (n=44) with early-stage, 
asymptomatic HIV infection, only R5 HIV-1 detectable, and no antiretroviral therapy for 12 weeks 
[Thompson, 2009]. Placebo (n=10) and three PRO 140 doses were examined: 162 mg weekly for 
three weeks (n=11), 324 mg weekly for three w eeks (n=11), and 324 mg bi weekly (every other 
week) for two doses (n=12). Subjects were followed for [ADDRESS_1072975] antiviral proof  of concept for a long-acting, se lf-administrable drug for HIV-1 
infection [Thompson, 2009]. 
Subcutaneous PRO [ADDRESS_1072976] common adverse events (diarrhea, headache, 
lymphadenopathy and hypertension) were mild to moderate and self-resolving. These events are 
common in HIV infection and were reported with similar frequencies in the placebo and PRO 140 
treatment groups. Administration-site  reactions were mild, transient,  and observed in a fraction of 
subjects. 
PRO 140_CD01 Study 
PRO 140_CD01 study (open-label, 43 subjects, mult i-center) evaluated the efficacy, safety, and 
tolerability of PRO 140 monotherapy (350 mg subcutaneous injection weekly for up to 12 weeks) 
for the maintenance of viral suppression followin g substitution of antiretroviral therapy in HIV-1 
infected patients (with exclusiv e CCR5-tropic virus). Participants in this study were experienced 
HIV-infected individuals who were  virologically suppressed on combin ation antiretroviral therapy. 
Consenting patients were shifted from combinati on antiretroviral regimen to PRO 140 monotherapy 
for 12 weeks. 
Forty-three (43) subjects (M/F: 37/3) with medi an age of 54.5 years (26-72) and median CD4 T- 
cell count of 604.5 cells/mm3 (365- 1240) were enrolled in the CD01 study. Overall, twenty-two 
out of 40 (55%) enrolled subjects comple ted 12 weeks of PRO 140 monotherapy without 
experiencing virologic failure. Virologic failure was defined as two consecutive HIV-1 RNA levels 
of ≥ 400 copi[INVESTIGATOR_014]/mL separated by [INVESTIGATOR_136] l east [ADDRESS_1072977] Dual/Mixed (D/M) tropi[INVESTIGATOR_8801] [1 at baseline  and 2 at the time of vi rologic failure] and 37 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1072978] ex clusive CCR5-tropic virus. A lett er of amendment was filed to 
increase the planned number of subjects from 40 to 43 s ubjects to compensate for the 3 Dual/Mixed 
subjects enrolled in the study. 
All virologic failure subjects who had available lab data in both studies achieved viral suppression 
to < 400 HIV-1 RNA copi[INVESTIGATOR_014]/mL, as well as vira l suppression to ‘Non Detectable’ or < 50 HIV-1 
RNA copi[INVESTIGATOR_014]/mL after re-initiation of Antiretroviral Therapy (ART). 
The by-subject analysis of PhenoSense® Entry Assay data for PRO140, maraviroc, and AMD3100 
shows no significant changes in the post-treatm ent IC50 and IC90 values were noted when 
compared with baseline values in  virologic failure and non-virologi c failure groups of subjects. As 
the aggregate analysis shows for initial 40 subjects,  the subjects who experienced virologic failure 
had higher IC90 value for PRO 140 at baseline compar ed to subjects without virologic failure. The 
mean IC90 for subjects who experienced virologic fa ilure was higher (10.84 µg/mL) than the IC90 
for subjects without virol ogic failure (6.70 µg/mL) in the CD01 study (p=0.0115). 
Anti-PRO [ADDRESS_1072979]-treatment sample and data derived from 
the CD01 study further supports the favorable PRO 140 PK profile data generated from both pre- 
clinical as well as prior Phase 1/2 clinical trials. 
Safety data were analyzed for all 43 enrolled subj ects. One (1) of 43 subjec ts experienced a Serious 
Adverse Event (SAE) that was deemed not related to the study drug by [CONTACT_079]. 
Twenty-eight (28) of 43 subjects (67%) experienced one or more AEs after receiving at least one 
dose of PRO140. The most commonly occurring AE s were infections and infestation conditions 
which were reported by 14 of 43 (32.5%) subjects. The majority of the reported AEs (62/87; 71.2%) 
were deemed either unlikely or not related to study treatment by [CONTACT_18413]. Similarly, the 
majority of the reported AEs (70/87; 80.4%) were deemed mild in nature. 
PRO 140_CD01 Extension Study 
PRO 140_CD01-Extension study (open-label, 28 subj ects, multi-center) seeks to evaluate the 
efficacy, safety, and tolerability of PRO 140 monothe rapy (350 mg subcutaneous injection weekly) 
for the continued maintenance of viral suppressi on following substitution of antiretroviral therapy 
in HIV patients (with exclusive CCR5-tropic virus). Participants in this study were HIV-infected 
individuals who were virologically suppressed on combination antiretroviral therapy and completed 
the first 12 weeks of CD01 study w ithout experiencing virologic fail ure. As with the CD01 study, 
virologic failure was defined as tw o consecutive HIV-1 RNA levels of ≥ 400 copi[INVESTIGATOR_014]/mL separated 
by [CONTACT_2669] 3 days. Consenting patients ma y remain on PRO 140 monotherapy until PRO 140 
receives marketing approval or Investigationa l New Drug (IND) application is withdrawn by 
[CONTACT_2728]. 
A total of [ADDRESS_1072980] extension treatment. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 29 of 96  
  
Sixteen (16) eligible subjects (M/F: 14/2) with median age of 54.9 years (26-68) and median CD4 
T-cell count of 593 cells/mm3 (365-1059) were en rolled in an extension study. One patient 
discontinued at week 37 (with viral load of <40 copi[INVESTIGATOR_014]/mL) due to relocation. Two subjects were 
withdrawn due to non-treatment related SAEs at week [ADDRESS_1072981] was 
withdrawn due to re-starting thei r ART at week 99. Two subjects withdrew consent at week 81 and 
139, respectively. Five (5) subject s experienced virologic failure (V F) (two consecutive viral load 
of ≥400 copi[INVESTIGATOR_014]/mL). The mean time to viro logic failure was 329 days (106-691). 
Five (5) subjects are currently receiving weekly [ADDRESS_1072982] completed more than three years of treatment (176 – 198 weeks). Overall, [ADDRESS_1072983] two years of treatment in this study 
PRO140 was generally well tolerated, and no drug-related SAEs were observed. 
This clinical study is currently ongoing. 
PRO 140_CD02 Study 
PRO 140_CD02 study (double blind, placebo contro lled, 52 subjects, multi-center) seeks to 
evaluate the efficacy, safety, and tolerability of PRO 140 in combin ation with either existing ART 
(failing regimen) or Optimized Background Therapy (OBT) in patients inf ected with HIV-1. The 
study population includes [ADDRESS_1072984] limited treatment options. The options 
may be limited as a result of drug antiviral class cross-resistance, documented treatment intolerance, 
documented objective assessments such as renal or  hepatic insufficiency (e.g. high creatinine at 
baseline, limiting treatment options  due to potential for toxicity), past adverse reactions such as 
hypersensitivity reactions or neuropsychiatric issu es that could limit us e of currently approved 
drugs. 
In Part [ADDRESS_1072985] an OBT. The primary 
efficacy endpoint is proportion of participants with ≥ 0.5 log10 reduction in HIV-1 RNA viral load 
from baseline at the end of the 7 day functional monotherapy period. 
In Part 2 of double-blind treatm ent period, subjects will conti nue treatment with PRO 140 in 
combination with OBT within the 24-week open-label period. 
Fifty-two subjects w ith a mean age of 52.4 years, 73.1% male, 48.1% non-white and mean duration 
of HIV-1 infection of 20.4 years were randomized  1:1 to the PRO 140 SC or placebo arm. Subjects 
had been previously exposed to an average of 11 ART drugs and had docum ented resistance to >9 
ART drugs. Mean baseline Viral Load (VL) and CD4 cell count were 21,104 c/mL and 297.8 
c/mm3, respectively. The pr imary efficacy endpoint- th e proportion of patients with ≥0.5 log10 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 30 of 96  
  
reduction in HIV-1 VL from baseline at the end of the 1-week double-blind, randomized, placebo- 
controlled treatment period- was met (16/25 vs 6/26 [p-value <0.0032, ITT population]). Forty 
seven (47) of [ADDRESS_1072986] completed the 25-week study. Approximately 81% of patients 
completing 25-weeks of PRO 140 SC  treatment demonstrated HIV- 1 VL <50 c/mL and 92% had 
HIV-1 VL <400 c/mL. Continued access to PRO 140 SC was provided through a rollover study 
and 40 patients entered the extension protocol after completing the CD02 study. PRO 140 SC was 
generally well tolerated. No drug-related SAEs or  treatment discontinuations  were reported in the 
study. This clinical study is completed. 
PRO 140_CD06 Study 
PRO 140_CD06 study (double-blind, 80 subjects, single-center) seeks to  evaluate the comparability 
of PRO 140 formulation Batch Lo t # 3-FIN-3143 versus formulati on Batch Lot# 3-FIN-2618 as a 
one-time subcutaneous (SC) injection in healthy subjects under non-fasting conditions. This clinical 
study is completed. 
PRO 140_CD02 Extension Study 
PRO 140_CD02 Extension study (open label, 40 subjec ts, multi-center) seeks to evaluate the long 
term efficacy, safety an d tolerability of PRO 140 weekly injection in combination with Optimized 
Background Therapy (OBT) in patients infected  with HIV-1. The study population includes 40 
treatment-experienced HI V-infected adult patients with CCR5-tropic virus who successfully 
completed PRO 140_CD02 study and continues to  demonstrate HIV-1 viral suppression. 
This clinical study is curren tly ongoing. 
 
PRO 140_CD03 HIV Study 
PRO 140 _CD03 HIV (open-label, 566 subjects, multi-ce nter) is a three part  study enrolling virally 
suppressed HIV-1 patients with CCR5-tropic HIV-1 receiving combination antiretroviral (cART) 
therapy. Patients received weekly doses of PR O 140 on single-agent main tenance therapy following 
one week of overlap of the existing cART regimen that is then discontinued. In part 1, 156 
participants received 35 0 mg PRO 140 SC in a single-arm desi gn. In part 2, 147 participants 
received 350 or 525 mg PRO 140 SC in a 1:[ADDRESS_1072987] been rando mized to receive 525 or 700 mg PRO 140 SC in a 
1:1 ratio. 
Of the 566 patients enrolled, median age was 52 yr s (21-81) with the majo rity reported as male 
(78%) and 38% were non-white. A total of [ADDRESS_1072988] been exposed to 700mg dose after rescuing from the lower doses 
(350 mg or 525mg). On average,  participants were diagnosed  with HIV-1 infection for 
approximately 17 yrs and were on cART regimen for approximately15 yr s. The frequency and 
severity of injection s ite reactions were comparable between  the three dose groups (350, 525 and 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 31 of 96  
  
700mg) and the incidence or severity of injection site reactions  was not increased in patients 
receiving higher doses. Overall, PR O 140 SC was generally well tolera ted at all dose levels in this 
study. 
This clinical study is curren tly ongoing. 
 
PRO 140_CD03 HIV Extension Study 
PRO 140_CD03 study (open-label, 350 subjects, mult i-center) seeks to ev aluate the long term 
efficacy, safety and tolerability of PRO 140 SC as long-acting single-agent maintenance therapy in 
virologically suppressed subjects with CCR5-tro pic HIV-1 infection. The study population includes 
up to 300 treatment-experienced HIV-infected adult patients w ho successfully completed PRO 
140_CD03 HIV study and continue to dem onstrate HIV-1 vira l suppression. 
This clinical study is curren tly ongoing. 
 
CD07_TNBC Study 
CD07_TNBC study (open-label, two-part [Phase Ib : Up to 18 subjects; Phase II: 30 Subjects], 
multi-center) seeks to evaluate the efficacy, sa fety, tolerability and Maximum Tolerated Dose 
(MTD) of leronlimab (PRO 140) when combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC). 
The study population includes patients with CCR5-pos itive, locally advanced or metastatic triple- 
negative breast cancer (mTNBC) who are naïve to ch emotherapy in metastatic setting but have been 
exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line). This clinical study is curren tly ongoing. 
 
CD08 mCRC  Study 
CD08_mCRC study (open-label, 30 Subjects, multi-cente r) seeks to evaluate the effect on Overall 
Response Rate (ORR) of Leronlimab  (PRO 140) when combined with  Regorafenib in patients with 
CCR5+, Microsatellite Stable (MSS), Me tastatic Colorectal Cancer (mCRC). 
The study population includes patie nts with CCR5+, MSS, mCRC who have been previously 
treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-Vascular 
Endothelial Growth Factor (VEGF) therapy, and,  if RAS wild type, an anti- Epi[INVESTIGATOR_54568] (EGFR) therapy. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 35 of 96  
  
Leronlimab 700mg Exposure Summary in Clinical Trials 
 
 Duration of 
Treatment Approximate Number of 
Subjects Received 700mg 
dose of Leronlimab 
CD10_COVID-19 
A Randomized, Double Blind, Placebo Controlled Study to 
Evaluate the Efficacy and Safety of Leronlimab for Mild to 
Moderate Coronavirus Disease 2019 (COVID-19) 2 Weeks 56 
CD12_COVID-19 
A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, 
Adaptive Design Study to Evaluate  the Efficacy and Safety of 
Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19) 2 Weeks 130 
PRO 140_CD03 
A Multicenter Study to Assess the Clinical Safety and Treatment 
Strategy of Using PRO 140 SC as Long-Acting Single-Agent 
Maintenance Therapy for 48 Weeks in Virologically Suppressed Subjects with CCR5-tr opic HIV-1 infection Up to 48 Weeks 132 
+ 
79 (Rescue dose) 
PRO 140_CD03 extension 
An Extension Protocol for Virologically Suppressed Subjects 
Who Successfully Completed PRO140_CD03 Study Up to 100+ 
Weeks 29 
Total Number of Subjects receiving Leronlimab 700mg dose: 426 
The safety profile of Leronlimab (PRO 140) has b een extensively evaluated in clinical trials of 
HIV-positive patients. Data accumulated for PRO [ADDRESS_1072989] HIV-1 infection. PRO 140 has been administered intravenously or 
subcutaneously to more than 750 healthy and HIV-1 infected individuals in Phase I/II/III studies. 
The drug has been well tolerated fo llowing intravenous administration of single doses of 0.5 to 10 
mg/kg or up to [ADDRESS_1072990] duration of exposure lasting >[ADDRESS_1072991] exposure to PRO 140 700 mg SC weekly dose is 48 weeks. 
Subjects treated with 525 mg and 700 mg Leronlim ab (PRO 140) have not experienced any SAEs 
related to Leronlimab (PRO 140). The majority of AEs have been mild in severity. In addition, 
there have been no presented patterns of drug-rela ted toxicities observed during treatment with 525 
mg and 700 mg Leronlimab (PRO 140). The most common AEs have been injection site reactions, 
the majority which have been mild and consider ed as self-resolving. C onsidering the favorable 
safety profile of PRO 140 to date, this study is me ant to further evaluate safety and potential efficacy 
of Leronlimab (PRO 140 at 700 mg) compared  to placebo in adult patients with NASH. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 36 of 96  
  
We anticipate a mana geable safety profile with Leron limab (PRO 140) therapy since: 1) 
Leronlimab (PRO 140) is not metabolized by [CONTACT_4852], and therefore may have the potential for a 
better tolerability profile than many of the ex isting small-molecule therapi[INVESTIGATOR_014]; 2) Unlike small 
molecules, monoclonal antibodies are too large to be  filtered by [CONTACT_780584], except in pathologic conditions . If low molecular weight  antibody fragments are 
filtered, they are usually reab sorbed and metabolized  in the proximal tubule of the nephron. 
Considering the results of stud ies on CCR5 blocker we believe, CCR5 inhibition may provide us 
with a new strategy for the treatment of NASH. 
 
1.7 RISKS / BENEFITS ASSESSMENT 
 
Risks/Discomfort to Subjects and Precautions to Minimize Risk 
 
Allergic Reaction 
Leronlimab (PRO 140) belongs to the monoclona l antibody class of drugs . Monoclonal antibodies 
are sometimes associated with allergic reactions or flu-like reactions (such as fever, chills, and 
aches) or injection-site reactions. These events are usually of short duration if they occur at all. 
Severe allergic reactions, however, can be life-threatening. Although anaphylaxis has not been 
observed in prior trials of Lero nlimab (PRO 140), infusion of proteins always  carries with it the 
theoretical risk for an aphylactic shock. Accordingly, whenever Leronlimab (PRO 140) is 
administered to subjects, there should be available and in place the procedur es required to manage 
anaphylactic shock. 
 
Immune Response 
People who take Leronlimab (PRO 140) or other monoclonal antibodies can also develop an 
immune response to Leronlimab (PRO 140) that may affect their ability to receive monoclonal 
antibodies, or to benefit from diagnosis or therapy with a monoclonal antibody in the future. 
 
Pregnancy 
Risks to unborn babies are unknown at this time; pregnant females will be excluded from this study. 
Females of childbearing potential must have a ne gative pregnancy test prior to enrollment. Both 
male and female patients and their partners of childbearing potentia l must agree to use appropriate 
birth control methods throughout th e study duration (excluding wome n who are not of childbearing 
potential and men who have been sterilized). 
 
Venipuncture 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1072992] Nile 
virus [Thompson, 2009]. Because of this, treatment with CCR5 co-receptor antagonists poses a 
theoretical risk for incr eased severity of West Nile virus infection. However, this concern is 
mitigated by [CONTACT_71411]. Firs t, no increased risk was observe d for individuals who possess one 
functional and one non-functional CCR5 gene, indicati ng that an intermediate  amount of CCR5 is 
sufficient for defense against West Nile virus [Thompson, 2009]. Second, use of CCR5 co-receptor 
antagonists is unlikely to completely abrogate CCR5 function, and there has been no association 
reported to date between CCR5 co-receptor use and severe West Nile virus. Additionally, 
Leronlimab (PRO 140) weakly antagonizes the natu ral activity of CCR5 and thus is less likely to 
adversely affect immune function. However, patients enrolled in this  study may have immune 
suppression from chemotherapy and theref ore, the investigators will be alerted to risks of West Nile 
infections. Furthermore, this has not been established to be a risk  with maraviroc, the other FDA- 
approved anti-CCR5 drug already. 
Collectively, the experience with both IV and SC , simulation modeling and the recent confirmation 
that a higher concentration of Leronlimab (PRO 140) synthesized using a highly efficient CHO cell 
line can be conveniently and safely administered has resulted in the design  of the current study. 
Intended Benefit for Subjects 
This study provides an opportunity  for subjects with NASH to have  once weekly SC treatment with 
Leronlimab (PRO 140). Subjects participating in the present st udy will contribute to the 
development of a drug which has the potential to b ecome a treatment option fo r them and others in 
the future. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 38 of 96  
  
2 STUDY OBJECTIVES 
 
2.1 PRIMARY OBJECTIVE : 
 The Primary objective of this study is to assess the efficacy of Leronlimab (PRO 140) in 
improving liver function in adult patients diagnosed with NASH compared to placebo 
 
2.2 SECONDARY  OBJECTIVE : 
 The Secondary objective of this study is to assess the safety and tolerability of  
Leronlimab (PRO 140) in adult patients di agnosed with NASH compared to placebo 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 39 of 96  
  
3 STUDY DESIGN 
 
This is a phase II, multi-cente r, two-part study (Part 1: ra ndomized, double-blind, placebo- 
controlled, two-arm with 60 patients; Part 2: non-randomized, single-arm,  open-label with 30 
patients) designed to evaluate the safety and efficacy of leronlimab  (PRO 140) SC in patients with 
NASH for 13 weeks. In Part 1 of  the study, leronlimab (PRO 140 at 700 mg dose) or placebo will 
be weekly administered subcutaneously by a licens ed healthcare professional at the clinic sites. 
A single arm, non-randomized, open-la bel phase (Part 2) is added to the protocol after completion 
of enrollment in the Randomized Phase (Part 1) of the study. In Part 2 of the study, leronlimab (PRO 
140 350 mg dose) will be weekly administered subcutaneously (SC) by a licensed healthcare 
professional at the clinic sites. 
 Part 1 : randomized, double-blind, placebo-cont rolled, two-arm (up to 60 subjects) 
 Leronlimab (PRO 140 700 mg) or Placebo SC weekly injection for 13 weeks 
 Part 2 : non-randomized, open-label, single-arm (up to 30 subjects) 
 Leronlimab (PRO 140 350 mg) SC weekly injection for 13 weeks 
This study consists of screening,  treatment, and follow-up periods. 
The study flow diagra m is presented in Figure 3-1 . 
 
3.1 STUDY CENTERS 
Up to 20 centers in the [LOCATION_002] (US). 
 
3.[ADDRESS_1072993] meet all of the inclusion and none of the exclusion criteria to be 
enrolled in the study. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 40 of 96  
  
Figure 3-1: Study Design Schematic 
 
 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 41 of 96  
  
3.3 ELIGIBILITY CRITERIA 
 
Inclusion Criteria 
Subjects are required to meet ALL of the following criteria for enrollment into the study: 
1. Subject is a male or female between 18 to 75 years of age inclusive. 
2. Evidence of nonalcoholic steatohepatitis (NAS H) based on one of the following criteria: 
 Criteria 1: Histologically -confirmed diagnosis of NASH on a liver biopsy, or 
 Criteria 2: FibroScan or Shearwave US duri ng screening (or within 6 months before 
screening) shows kPa ≥7 but <14 and CAP ≥260. 
3. Subject shows presence of hepatic fat fraction as defined by ≥ 8% on MRI-PDFF and cT1 
≥ 800 ms at Screening. 
4. Has had a stable body weight (±5%) with in 6 months prior to Screening. 
5. Body Mass Index (BMI) ≥ 28 kg/m2 at Screening 
6. Has clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered 
not clinically significant by [CONTACT_079]. 
7. Laboratory Screening results as indicated below: 
a. AST:ALT Ratio ≤ 1, if AST or ALT value is > ULN 
b. Screening Liver enzymes (AST, ALT, and ALK PHOS) < [ADDRESS_1072994]. 
c. Total Bilirubin ≤ 1.3 mg/dL (except if Gilbert’s Disease) 
d. Platelet count ≥ 150,000/mm3 
e. International normalized ratio (INR) < 1.3 
f. Estimated Glomerular Filtration Rate (eGFR) ≥ 60/mL/min 
g. Glycosylated hemoglobin (HbA1c) < 9%. 
h. TSH within normal reference range. 
Note: Any subject with a non-cl inically significant TSH value outside of the normal range 
may be enrolled if their T3 and free T4 values are within the normal range. 
8. Subjects with pre-diabetes or type 2 diabetes will be allowed to participate if the following 
criteria is met: 
 Subjects who are taking anti-dia betic medications should be on a stable dose for a period 
of at least 3 months prior to  Screening and do not anticipate  clinically significant dose 
adjustments during the course of study. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 42 of 96  
  
  Subjects must be on a stable diet/lifestyle regimen for at leas t 3 months prior to 
screening and do not anticipate a clinically si gnificant change during the course of study. 
9. Subjects who are taking Vitamin E should be on a stable dose of Vitamin E (if ≥ 400 IU) 
for a period of at least [ADDRESS_1072995] agree to use 
two medically accepted methods of contracep tion (e.g., barrier contraceptives [male 
condom, female condom, or diaphragm with a spermicidal ge l], hormonal contraceptives 
[implants, injectables, combination oral contraceptives, transd ermal patches, or 
contraceptive rings], or one of the following me thods of birth control (intrauterine devices, 
tubal sterilization or vasectomy) or must practice complete abstinence from intercourse of 
reproductive potential from study entry to [ADDRESS_1072996] day of treatment (excluding 
women who are not of childbearing potential  and men who have been sterilized). 
11. Females of child-bearing potential must have a negative serum pregnancy test at Screening 
Visit and negative urine pregnancy test prior to receiving the first dose of study drug; and 
Male participants must agree to use contraception and refrain from donating sperm for at 
least [ADDRESS_1072997] is willing and able to  comply with scheduled visits, drug administration plan, 
laboratory tests, other study pro cedures and study restrictions. 
 
 
Exclusion Criteria 
Subjects meeting ANY of the following criteria will be excluded from enrollment: 
1. Any concurrent clinically significant liver disease with an etiology other than NASH 
including autoimmune hepatitis , alcoholic hepatitis, hypoxic/ ischemic hepatopathy, and 
biliary tract disease. 
2. History of alcohol consumption greater than 21/units/week (for males) and 14/units/week 
(for females) within the last 2 years prior to screening. 
Note: Use of online unit calculator for al cohol consumption is recommended (e.g., 
https://alcoholchange.org.uk/alcohol-fac ts/interactive-tools/unit-calculator ) 
3. Any drug-induced steatohepatitis secondary to amiodarone, co rticosteroids, estrogens, 
methotrexate, tetracycline, or other medi cations known to cause hepatic steatosis. 
4. Undergone major surgery, includ ing liver surgery, within 6 months prior to screening. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 43 of 96  
  
5. Prior or pending liver transplantation. 
6. History or presence of cirrhosis or stage 4 fibr osis in historical liver biopsy and/or hepatic 
decompensation including ascites, hepatic  encephalopathy or variceal bleeding. 
7. Active hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg] test), 
hepatitis C (defined as having a positive Anti-H CV test with detectable reflex HCV RNA; 
Note: Subject with positive Anti-HCV test an d with undetectable HCV RNA would not be 
excluded), acute hepatitis A (defined as subj ects with serum positive for hepatitis A IgM 
(HAV) antibody) or acute hepatitis E (def ined as having anti-HEV IgM antibody). 
8. Any active infection requiring systemic therapy at  the time of screening, which is considered 
clinically significant per the Investigator. 
9. Positive test for human immunodeficien cy virus (HIV) or HIV infection. 
10. History of bleeding diathesis within [ADDRESS_1072998] 5 years, excl uding successfully treated  basal cell carcinoma 
or squamous cell carcinoma without evidence of metastases. 
12. Seizure disorder requiring ongoing antiseizure therapy or with any condition that, in the 
judgment of the investigator, is  likely to increase the risk of  seizure (e.g. CNS malignancy) 
13. Clinically significant active cardiac disease which would interfere with study conduct or 
study results interpretation per the PI. 
14. Any known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 
15. Prior therapy with Leronlimab  or any other CCR5 antagonist (e.g. maraviroc) within 6 
months prior to screening. 
16. History of severe allergic, anaphylactic, or other hypersensitivity reactions to humanized 
monoclonal antibodies. 
17. Any condition requiring continuous  systemic treatment with immunosuppressive (such as 
corticosteroids) or immu nomodulatory medications. 
Note: Inhaled or topi[INVESTIGATOR_780573] 5 mg daily prednisone equivalent dose are permitted in the absence of active autoimmune disease. 
18. History of administration of a live, attenuated vaccine within four weeks prior to start of PRO 140 treatment or anticipation that such a live attenuated vaccine will be required during 
the remainder of the study. 
Note: Seasonal influenza vaccines for injecti on are generally inactivated flu vaccines and 
are allowed; however intranasal influenza va ccines (e.g., Flu-Mist ®) are live atte nuated 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 44 of 96  
  
vaccines, and are not allowed. 
19. Currently participating in an i nvestigational study or received an investigational drug within 
28 days or 5 half-lives (whichever is  longer) prior to study drug administration. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 46 of 96  
  
Subjects who complete the treatment period will  continue to End of Treatment (EOT) Visit 
assessments at week 14 and enter the Follow-up Phase of the study. Subjects who meet any criteria 
for discontinuation of study treatment as specified in Section 5.1 of the protocol, will undergo Early 
Termination (ET) Visit assessments [ADDRESS_1072999] injection and ente r the Follow-up Phase of 
the study. 
Follow-Up Period: Follow-up visit will be conducted 28 (± 3) days after the End of Treatment 
(EOT) or Early Termination (ET) Visit. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 49 of 96  
  
Other: Fasting blood Glucose , Serum HbA1C, Thyroid profile 
Note: Screening laboratory testing can be repeated once during the 28-day screening wi ndow based on the Investigator’s clinical  judgement). 
[12] Urine samples will be tested for pH, appearance, color, specific  gravity, turbidity, ketones, bilirubin, occult blood, glucose,  protein, nitrites, urobilinogen, and 
leukocyte esterases. Microscopic examination of urine sediment w ill be performed if there are abnormalities in macroscopic urin alysis results. Microscopic urine 
tests include bacteria, cast, crysta ls, epi[INVESTIGATOR_1663], RBC and WBC. 
[13] Only performed on women of childbearing potential 
[14] Blood sample collected at T1 (prior to fi rst dose of PRO 140), pre-dose at T2, T6, T10,  and at EOT (or ET) and Follow-up visit 
[15] Randomization via WebView CTMS system only applicable for Part [ADDRESS_1073000] udy 
[16] Leronlimab (PRO 140) or placebo is administered as subcutaneous injection in the abdomen weekly. In Part 1 of the study, a tota l of 700 mg dose of leronlimab 
(PRO 140) or placebo will be delivered as tw o injections of 2 mL. In the Part 2 of the study, a total dose of 350 mg dose of le ronlimab (PRO 140) will be 
delivered as one injection of 2 mL. 
[17] Injection Site Reaction Assessment as assessed by  [CONTACT_10670] (or designee) at the clinic . 
[18] Subject-perceived injection site pain (average pain since last  treatment) will be assessed us ing 11-point Numeric Rating Scale from 0 to 10 prior to each study 
treatment administration. “0” meaning “no pain” and “10” meaning “worst possible” pain. 
[19] AE and CM evaluations to be conducted at each clinic visit applicable 
[20] Subjects discontinuing the study at any time for any reason (early termination-ET) should complete  the procedures listed AND th e follow-up visit 
[21] In case subjects have already completed thei r EOT/ET and FU visits, site  should use the Unscheduled Visit option to collect blood sample for Monocyte/T Cell 
CCR5 analysis. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1073001] will sign and date the Informed Consen t Form (ICF) and Health Insurance Portability 
and Accountability Act (HIPAA) aut horization (according to site policy and practices ) prior to any 
study-related procedures. A unique identificatio n number (screening number) will be assigned to 
each subject who has provided written informed consent. The screening number will incorporate a 
three-digit Study Center number (101, 102, etc.) and a three-digit numeric ID assigned in successive 
order of consenting to screening procedures after signing the ICF at  each center, beginning with 001 
at each site (e.g. 101-001 or 102-001, etc.). 
 
XXX - YYY 
Subject Screenin g #:   
XXX=Study Center  YYY=Subject Numeric ID 
 
All study centers will be in structed to maintain the study-specific screening and enrollment logs at 
their sites. If a subject initially fails to meet inclusion/exclusion cr iteria and is later reconsidered for 
participation, the subject will be  re-consented and assigned a new screening number at the time of 
re-screening. Subjects who fail their first screeni ng attempt may be re-screened a maximum of once 
and may be enrolled if they are found to meet all inclusion and no exclusion criteria when re- 
screened. 
Once the Screening ICF has been signed, screening procedures and informat ion will be obtained to 
confirm subject eligibility including: 
 Demographic information and baseli ne disease characteristics (see Section 7.3 ), 
 Medical history (see Section 7.4 ), 
 Prior and concomitant medications assessment (see Section 7.5 ), 
 Vital Signs (see Section 7.6 ), 
 Body Weight & Height  measurements (see Section 7.6 ), 
 Physical examination (see Section 7.7),  
 12-lead Electrocardiogram (see Section 7.8 ) 
 FibroScan (or equivalent non- invasive imaging test) (see Section 7.13)  
 Collection of lab specimens (see Section 7.9) for 
o Complete blood c ount 
o Biochemistry 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1073002] 
o HBS Ag, HCV Ab and HCV RNA (if requ ired), HIV Ab, HAV IgM antibody, and 
HEV Ab 
 Liver MRI (see section 7.14)  
All screening information will be fully documented in the subject’s medical records (i.e., source 
documents). 
 For consented subjects who do not meet eligibil ity criteria, a Screen Failure Case Report 
Form (CRF) will be completed. The Screen Failure CRF will contain the following details: the subject identification number, the date of  ICF signature, demogr aphic information (see 
Section 7.3), and the reason for screen failure. No additional information will be required for subjects who fail screening. 
 For consented subjects who meet eligibility criteria, all requir ed screening information will 
be transcribed onto the appr opriate page of the CRF. 
 
4.2 TREATMENT  PERIOD 
Subjects who meet all eligibility criteria, as per data gathered from Screening Period are to be 
treated. All subjects who fail to meet eligibility criteria will be considered screen failure and exit 
the study without further evaluation 
The maximum sample size for this  study is 90 subjects that will be  followed by [CONTACT_780585]. 
In Part 1 of the study, eligible subjects will be  randomized to 1:1 to one of the two study arms to 
receive Leronlimab (PRO 140) 700 mg (Group A), or placebo (Group B) as two subcutaneous 
injections, given once per week (± 1 day) fo r up to 13 weeks during the treatment period. 
 PRO 140 700mg SC weekly injection (Group A) 
 Placebo 0 mg SC weekly injection (Group B) 
The study treatment (PRO 140 700 mg or placebo SC injections) will be admi nistered by a licensed 
healthcare professional once a week at the study site. 
In Part 2 of the study, eligible subjects will be enrolled to receive leronlim ab (PRO 140) 350 mg as 
one injection, given once per week (± 1 day) for up to 13 weeks during the treatment period. 
 PRO 140 350mg SC weekly injection 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 52 of 96  
 The study treatment (PRO 140 350 mg SC injection) will be administered by a licensed healthcare 
professional once a week at the study site. 
Treatment Visit 1 (T1) 
The following assessments will be performed at the first treatment visit, unless otherwise specified: 
Pre-Treatment  
 Confirmation of eligibility criteria by [CONTACT_780586] r criteria assessments 
performed at Screening Visit (see Section 7.2 ) 
 Vital Signs and body wei ght measurement (see Section 7.6 ), 
 Physical examination (see section 7.7 ), 
 12-lead Electrocardiogram (see Section 7.8 ) 
 Change in concomitant medications (see Section 7.5 ), 
 Any changes in medical histor y since Screening Visit (see Section 7.4 ), 
 Randomization only applicable for Part 1 of the study (see Section 8.4 ) 
 Collection of lab specimens (see Section 7.9) for 
o Complete blood c ount 
o Biochemistry 
o Urine pregnancy test, for female subjects of childbearing potential 
o Urine sample for urinalysis parameters 
o FibroTest 
o Anti-Drug Antibodies (ADA) to PRO 140 
o PK evaluations 
o Serum pro-inflammatory cytokine/chemokine evaluations 
o Monocyte/T cell CCR5 biomarker assay 
Administration of study trea tment [PRO 140 or placebo] 
PRO 140 or placebo is administered as subcutaneous injection in th e abdomen weekly. In part 1 of 
the study, a total of 700 mg (175 mg/mL) or placebo is delivered as two injections of 2 mL on 
opposite sides of the abdomen. In Part 2 of the study, a dose of 350 mg of leronlimab (PRO 140) 
(175 mg/mL) will be delivered as  one injection of 2 mL and administered subcutaneously in the 
abdomen. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 53 of 96  
 Note: All study treatments (PRO 140 or placebo) must  be administered by a licensed healthcare 
professional. 
Post-Treatment  
 Injection Site Reaction Assessment (see Section 7.11) 
 Assessment of Adverse Events (AE) ( see Section 9.1 ) 
 Vital Signs (see Section 7.6 ) will be assessed within 15 minutes of study treatment 
administration. 
After treatment administration, subjects who m eet any criteria for discontinuation of study 
treatment as specified in Section 5.1 of the protocol, will undergo End of Treatment (EOT) Visit 
assessments and enter the Fo llow-up Phase of the study. 
Treatment Visit 2 (T2) to Treatment Visit 13 (T13) 
The following assessments will be performed at each visit, unless otherwise specified: 
 Assess for any AEs (see Section 9.1 ) 
 Concomitant medications assessment (see Section 7.5 ) 
 Vital Signs and body weight measurement (see Section 7.6) (weight only on visits T2, T6, 
T10 ) 
 Symptom-directed physical examin ation at clinic visits (see Section 7.7 ) (only on visits T2, 
T6, T10) 
 12-lead Electrocardiogram (see Section 7.8) (only on visits T2, T6, T10) 
 Collection of lab specimen s at T2 , T6, T10 (see Section 7.9 ) for: 
o Complete blood c ount 
o Biochemistry 
o Urine sample for urinalysis parameters 
o Urine pregnancy test, for female subject s of childbearing potential (T6 and T10 
only) 
o FibroTest 
o Anti-Drug Antibodies (ADA) to PRO 140 
o PK assessment 
o Serum pro-inflammatory cytokine/chemokine evaluations 
o Monocyte/T cell CCR5 biomarker assay 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 54 of 96  
  Leronlimab (PRO 140) Administration (see Section 6.4 ) 
 Injection Site Reaction Assessment (see Section 7.11) 
 Subject-perceived Injection Site Pain Assessment (see Section 7.12) 
Note: Subject-perceived injection site pain will be  assessed using 11-point Numeric Pain Rating 
Scale from [ADDRESS_1073003] treatment. “0” meaning “no pain ” and “10” meaning “w orst possible pain”. 
End of Treatment (EOT) Visit 
Subjects who complete the treatment period will  undergo End of Treatment (EOT) Visit. The 
following assessments will be performed for the subjects: 
 Assess for any Adverse Events (see Section 9.1 ) 
 Changes in Concomitant medications (see Section 7.5 ), 
 Physical examination (see Section 7.7 ), 
 Vital Signs and body weight measurement (see Section 7.6 ), 
 Subject-perceived Injection Site Pain Assessment (see Section 7.12), 
 12-lead Electrocardiogram (see section 7.8 ), 
 Liver MRI (see section 7.14)  
 Collection of Blood Specimens (see section 0) for: 
o Complete Blood Count 
o Biochemistry 
o FibroTest 
o Anti-Drug Antibodies (ADA) to PRO 140 
o PK assessment 
o Serum pro-inflammatory cytokine/chemokine evaluations 
o Monocyte/T cell CCR5 biomarker assay 
Note: In case subjects have already completed their EOT/ET and FU visits, site should 
use the Unscheduled Visit option to colle ct blood sample for Monocyte/T Cell CCR5 
analysis. 
 
 Urine pregnancy test, for female subjects of childbearing potential. 
 Urine sample for urinalysis parameters 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 55 of 96  
 Early Termination (ET) Visit 
Subjects who meet any criteria for discontin uation of study treatment as specified in Section 5.1 of 
the protocol, will undergo Early Termination (ET) Visit. 
The following assessments will be performed: 
 Assess for any Adverse Events (see Section 9.1 ) 
 Changes in Concomitant medications (see Section 7.5 ), 
 Symptom-directed physical examination (see Section 7.7), 
 Vital Signs and body weight measurement (see Section 7.6 ), 
 12-lead Electrocardiogram (see section 7.8 ), 
 Liver MRI (see section 7.14)  
 Collection of Blood Specimens (see section 0) for: 
o Complete Blood Count 
o Biochemistry 
o FibroTest 
o Anti-Drug Antibodies (ADA) to PRO 140 
o PK assessment 
o Serum pro-inflammatory cytokine/chemokine evaluations 
o Monocyte/T cell CCR5 biomarker assay 
 Urine pregnancy test, for female subjects of childbearing potential. 
 Urine sample for urinalysis parameters 
 
4.3 FOLLOW -UP PERIOD 
Follow- up visit will be conducte d 28 (± 3) days after the E nd of Treatment (EOT) or Early 
Termination (ET) Visit. All subjects will be foll owed for biochemistry lab assessment, anti-drug 
antibodies (ADA) to PRO 140, PK assessment, se rum pro-inflammatory assessment, blood sample 
for Monocyte/T cell CCR5 biomarker assay vital si gns, symptom-directed physical exam, adverse 
events, and concomitant medications assessment. Subjects who discontinue treatment for unaccep table adverse event(s) will be followed until 
resolution or stabilization of the adverse event (i.e. the grade is not changing). 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1073004] will return to clin ic at a time other than a regularly scheduled study 
visit, the visit will be regarded as an unscheduled visit. Assessments at unscheduled visits are at 
the discretion of the Investigator. All pertinen t findings, including adverse events or changes in 
medications, will be noted in the eCRF.  
Any hospi[INVESTIGATOR_780574] s hould be promptly notified to the 
site staff.  
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1073005] prematurely withdrawn (early terminated) from the Study. 
All subjects have the right to withdraw at any point during treatment wit hout prejudice to future 
care. It will be documented whether or not each subjec t completed the clinical study. If for any 
subject, study treatment or observations were discontinued, the reason(s) will be recorded. 
Subjects WILL be withdrawn from the study, in consultation with the Medical Monitor and the 
Investigator, if any of  the following are met: 
 A subject is significantly non-compliant with the requi rements of the protocol. 
 The Investigator determines that it is in the best interest of the subject. 
 Subject chooses to withdraw or is withdrawn due to an adverse event 
 A subject becomes pregnant 
Note: The pregnancy will be followed to term for safety follow-up. Relevant safety information 
collected after the study has completed will be reported as supplemental information. 
 Discontinuation of study by [CONTACT_2728] 
 Subject becomes lost to follow-up (LTF) 
 Subject experiences unacceptable toxicity 
 Subject voluntarily withdraws from treatment (follow-up permitted) 
 Subject withdraws consent (no follow-up permitted) 
Discontinuation of study treatment fo r the individual subject MAY occur if, in consultation with the 
Medical Monitor and the Investigat or, any of the following are met: 
 A subject is treated with a prohibited medication. 
 Diabetic subjects with an increased HbA1 C results of >9% or experiencing significant 
changes in glucose control requi ring modification to the dosage  or regimen of antidiabetic 
medication 
 Major protocol violation ( Section 0 ) 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 58 of 96  
  Subjects who have two occurrences of a Grade 2 or higher allergic/ hypersensitivity reaction 
directly related to the stu dy drug that lead to permanen t discontinuation of study drug.  
 Subjects experiencing grade 3 or higher AE (per CTCAE v5. 0) that is possibly or probably 
related to the study drug OR grade 4 or higher AE regardless of attribution to the study drug.  
 Subjects considered to potentially have Dr ug-Induced Liver Injury (DILI) as described 
below. 
Drug- induced liver Injury (DILI) 
If subjects with abnormal baseline liver indices de velop elevations of AST or ALT >2x baseline or 
Total Bilirubin (TBL) >1.5x baseline values during th e study, the tests will be repeated within 48- 
72 hours. If there are persistent elevations (AST or ALT>2x baseline or TB L >1.5 baseline values) 
upon repeat testing, then close observation of th e subjects per below should be implemented and 
discontinuation of the study treatment will be considered as per Section 5.1. During the close 
observation period, liver enzyme and serum bilirubin tests will need to be repeated two or three times 
weekly. Frequency of retesting can decrease to once a week or less if abnormalities stabilize or the 
study treatment has been discontinued and the subject is asymptomatic. 
Additionally, further gastroentero logy or hepatology consultations  and/or liver biopsy can be 
considered per Inves tigator’s discretion. 
If patient is unable to come to clinic for blood draw during the close obser vation period, laboratory 
testing can be performed loca lly, and the results should be promptly communi cated to the 
investigator site. A decision to di scontinue or temporarily interrupt the study drug will be considered 
based on factors that include how much higher than baseline the ALT and AST are relative to the 
upper limit of normal (ULN) and ho w much the AST and ALT levels have increased relative to 
baseline, in addition to whether there is a conc omitant elevation of bili rubin or INR. The study 
treatment will be discontinued or temporarily interrupted und er the following conditions: 
 If Baseline Measurements (BLM) were <[ADDRESS_1073006] increases to >5x BLM 
 If BLM was 2x ULN but <5x ULN,  The study treatment will be discontinued if ALT or AST 
increases to 3x BLM 
 If BLM was 5x ULN, The study trea tment will be discontinued if  ALT or AST increases to 
>2x BLM 
 If ALT or AST increases >2x BLM and the increase is accompanied by a concomitant 
increase in TB to >2x BLM or the INR concomitantly increases by 0.2, The study treatment 
will be discontinued 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 59 of 96  
  If any subject presents with signs or symptoms of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and or eosinophilia (>5% ), the study treatment 
should be discontinued 
Note: For the purpose of the assessment of drug-in duced liver injury (DILI), Baseline Measurements 
(BLM) for lab values (such as AST, ALT, total B ilirubin) refers to the average (mean) value of 
Screening Visit (SV) and T1 Visit.  If liver function tests are repe ated during Screening Phase, the 
average (mean) value of all Screening Visit tests a nd T1 Visit will be used to calculate the Baseline 
Measurements. 
All data normally collected at th e scheduled EOT Visit should be r ecorded at the time of premature 
discontinuation. 
If a subject fails to return for th e scheduled study visit or is discon tinued from the study, an attempt 
will be made to determine the reason(s). If the subject is unreachable by [CONTACT_756], a registered 
letter will be sent to th e subject requesting that he /she contact [CONTACT_3652]. 
All patients with an ongoing SAE at the Post-Study (Follow-up) Visit (scheduled or premature) 
must be followed until the event is resolved (w ith or without sequelae) or deemed stable. 
 
5.[ADDRESS_1073007] who signed a consent form, but did not meet the inclusion/ex clusion criteria is classified 
as a screen failure. Subject number, demographics and reason for screen failure will be recorded. 
In the event that a subject initially  fails to meet inclusion/exclusion criteria and is la ter reconsidered 
for participation, will be re-c onsented and assigned a new screen ing number at the time of re- 
screening. Subjects who fail their first screening attempt may be re-screened  again (i.e., up to two 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 60 of 96  
 screenings) and may be enrolled if they are found to meet all inclusion and no exclusion criteria at 
the subsequent screening visit. 
 
5.5 CLINICAL TRIAL STOPPI[INVESTIGATOR_780575] d if any of the following occurs: 
 Three patients develop the same Grade 3 AE attributed to the study drug per CTCAE v5.0 
OR 
 Two patients develop any Grade 4 AE a ttributed to study drug per CTCAE v5.0 
OR 
 One patient develops a grade 5 AE a ttributed to study drug per CTCAE v5.0 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 63 of 96  
 Protocol: CDI-NASH-[ADDRESS_1073008] No.   
Kit contains 2 single-us e vials of PRO 140 2mL at 175 mg/mL solution for 
subcutaneous injection 
USE AS PER STUDY PROTOCOL Store at 2oC to 8oC 
Caution: New Drug – Limited by [CONTACT_4496] (or [LOCATION_002]) Law to Investigational Use 
C
ytoDyn Inc., Vancouver, WA, [LOCATION_003] Below are representative samples of the I nvestigational Product, FDP individual vial ( Figure 6-1 ), 
and kit label ( 
Figure 6-2) designated for use in this clinical prot ocol. Each kit contains two labeled vials. 
Figure 6-1: Investigational Product - Vial Label 
 
 
Protocol:  CDI-NASH-[ADDRESS_1073009] No.   
Single use vial of PRO 140 2 mL at 175 mg/mL solution for 
subcutaneous injection 
Store at 2oC to 8oC 
Caution: New Drug – Limited by  [CONTACT_4496] (or [LOCATION_002]) 
Law to Investigational Use 
CytoDyn Inc., Vancouver, WA, [LOCATION_003] Protocol:  CDI-NASH-[ADDRESS_1073010] No.   
Single use vial of PRO 140 2 mL at 175 mg/mL solution for subcutaneous injection 
Store at 2
oC to 8oC 
Caution: New Drug – Limited by [CONTACT_4496] (or [LOCATION_002]) 
Law to Investigational Use 
CytoDyn Inc., Vancouver, WA, [LOCATION_003] 
 
Figure 6-2: Investigational Product - Kit Label 
 
 
The pharmacy manual provides the criteria regarding vial acceptance or rejection, as well as 
instructions for the preparation of the IP syringes to be used to administer drug. 
 
6.3 LERONLIMAB (PRO 140) - S TORAGE AND HANDLING 
Study drug will be shipped at 2°C to 8°C (refrigerat ed [36°F to 46°F]) to the investigator’s site. 
Upon receipt at the site, the respon sible site staff or pharmacist shou ld verify the integrity of the 
vials. Study drug should be stored at 2°C to 8°C (refrigerated [36°F to 46°F]). The contents of the vial should appear as a clear to opalescent, colorless to yellow solution; fine translucent particles may be present. This is normal. 
The investigator must maintain an accurate record of the shipment, storage, and dispensing of the study drug in a drug accountability log. An accurate record includi ng the date and amount of study 
drug dispensed to each subject mu st be available for inspection at any time. An unblinded study 
Clinical Research Associate (CRA ) assigned to monitor the investig ational site will review these 
documents once study drug has been received by [CONTACT_480342]. Study drug will be 
accounted for on an ongoing basis during the study. 
 
6.[ADDRESS_1073011]  ADMINISTRATION  
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 64 of 96  
 Guidelines for dose preparation can  be found in the pharmacy manual. 
Leronlimab (PRO 140) will be provided to the administering personnel in single-use syringes 
prepared from vials of study drug stored  at 2-8°C at the site pharmacy prior to use. In Part 1 of the 
study, each of two syringes is fi lled to deliver 2.0 mL of study drug. Equivalent volumes of PRO 
140 or placebo will be administered subcut aneously on opposite sides of the abdomen. 
In Part 2 of the study, one syringe is filled to deliver 2.0 mL of study drug . Leronlimab (PRO 140) 
will be administered subcutaneously in the abdomen. 
A 20-guage needle should be used to remove PRO 140 or placebo from vial and a 25-guage needle 
is used for administration to subjects. 
Note: After the leronlimab or placebo solution is drawn into the syringe, it can be stored at 
 room temperature (20°C to 25°C, 68 °F to 77°F) for up to 2 hours, or 
 refrigerated (2°C to 8°C, 36°F  to 46°F) for up to 4 hours. 
IP should be administered slowly over 15 seconds per mL. 
Following each SC delivery of drug, careful examina tion will be made to assess the appearance of 
any study drug Injection Site Reac tions (ISRs) as per CTCAE v5.0. 
In Part [ADDRESS_1073012] is not applicable 
for the Part 2 of the study. 
All Leronlimab (PRO 140) SC weekly  injections must be administer ed at clinic by a healthcare 
professional. Note: It is preferred that the same injection site be us ed throughout the study. At the same time, it 
is not recommended to inject th e study drug into areas where sk in shows signs of a previous 
injection site reaction. It is advise d to change the injection site if any previous inject ion site reaction 
remains unresolved. 
Post Injection Monitoring 
Subject will be observed at appr oximately [ADDRESS_1073013]-perceived  injection site pain using 11- point Numeric Pain Rating Scale. 
Dose Modifications 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1073014]’s  participation in the trial, the 
written informed consent must be signed and pe rsonally dated by [CONTACT_780587]. Aut horization for release of protected health 
information must also be obtai ned, as per local policies. 
 
7.[ADDRESS_1073015]’ continued eligibility for th e study as per the Inclusion and 
Exclusion criteria, during the Sc reening Period. The eligibility  criteria are described in Section 0 
(Inclusion Criteria) and Section 0 (Exclusion Criteria). In the event that the subject is not suitable 
or eligible for the study, the subject will be considered “screen failure”. 
Re-screening 
If a subject fails initially to meet the eligibility criteria, and is late r reconsidered for participation, 
the subject will be re-consented and assigned a ne w screening number at the time of re-screening. 
Subjects who fail their first scr eening attempt may be re-screened a maximum of once and may be 
enrolled in the study only if they meet all Incl usion and no Exclusion criteria when re-screened. 
 
7.3 DEMOGRAPHIC INFORMATION AND BASELINE DISEASE CHARACTERISTICS 
In this study the demographic information will include: 
 Dates of ICF signature 
 Date of birth 
 Gender 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 67 of 96  
  Race (American Indian/Alaskan Native, Asian, Black/African American, Native 
Hawaiian/Pacific Islander,  Caucasian, or other) 
 Ethnicity (Hispanic/Latino or Not Hispanic/Latino) 
In addition, the following baseline disease characteristics will be collected: 
 Disease diagnosis date 
 Medications used for the indication 
 Previous histological procedures, if available for the indication: 
o Date of the most recent procedure 
o Stage of liver fibrosis per the most recent procedure 
o Any indication for cirrhosis per the most recent procedure 
o Stage of steatosis per the most recent procedure 
 
7.4 MEDICAL HISTORY 
A complete review of the subjec t’s past medical hist ory (including prior and concurrent liver 
disease and cirrhosis), past surgeries, current therapi[INVESTIGATOR_014] (medications and non-medications), and 
history of exposure to environmen tal chemical agents will be undertaken by [CONTACT_780588]. 
Events that emerge prior to the first treatment (T 1) will be recorded in the medical history and not 
as AEs. Aside from being used to determine subject eligibility, this information will permit the 
Investigator to record the natu re, duration and severity of any ongoing baseline medical conditions 
prior to the subject’s receiving investigational product treatment. 
Medical histories will be recorded using the body system  categories outlined below: 
 
 Cardiovascular  Lymphatic 
 Respi[INVESTIGATOR_696]  Hematologic 
 Gastrointestinal  Immunologic 
 Renal  Dermatologic 
 Hepatic  Psychiatric 
 Neurological  Genitourinary 
 Endocrine  Other 
 
For each relevant history, the following will be documented: 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 68 of 96  
  Disease/disorder/condition 
 Date of diagnosis 
 History status (resolved or ongoing). 
 
7.[ADDRESS_1073016] begi nning 6 month prior to 
Screening Visit and throughout the study will be recorded in th e source documents and on the 
appropriate page of the Case Report Form (CRF) including all prescription, over-the-counter 
(OTC), herbal supplements, and IV  medications and fluids. If cha nges occur during the trial period, 
documentation of drug dosage, frequency, route,  and date may also be included on the CRF. 
Subjects must be questioned at each study visit concerning any new medications or changes in 
current medications including over-the-counter medication and topi[INVESTIGATOR_73201]. 
For each medication and non-study treatment , the following will be documented: 
 Medication/treatment name (generic name [CONTACT_26499]) 
 Dose, unit, and frequency of dosing (individual dosages, not total daily dose). 
Note: Each new dose of medication should be recorded as a separate entry, with the exception of 
medications that are given on a sliding scale. For these, it is acceptable to enter the range of the 
dosage, including the start and stop dates for which the specified dos age range was used . 
 Route of dosing 
 Indication for use 
 The start date 
 The stop dates (if medication/therapy is not ongoing). 
Permitted Medications 
All treatments that the investigator considers nece ssary for a subject’s welfare may be administered 
at the discretion of the investigator in keepi [INVESTIGATOR_77981]. 
Prohibited Medications 
Subjects are prohibited from receiv ing the following therapi[INVESTIGATOR_780576]: 
 Use of radiation or cytotoxic chemothe rapy, immunosuppressant s and immunomodulating 
agents (e.g., interleukins, interferons) 
 Use of any non-FDA approved/investigational therapy 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 69 of 96  
  Use of hepatotoxic  medications  such as antiarrhythmic  drugs  e.g., Amiodarone,  Dronedarone  
 Clinically significant dose adjustments of  the existing T2DM medication regimen or 
initiation of new anti-diabetic medica tions for the duration of the study. 
 
7.6 VITAL SIGNS , HEIGHT AND WEIGHT 
The following will be collected: 
 Vital signs: 
o Seated blood pressure (taken after the subj ect has been seated for at least 5 minutes) 
o Pulse 
o Temperature (oral or tympanic) 
o Respi[INVESTIGATOR_13581] 
 Height (only at the Screening Visit) 
 Weight 
 BMI (derived from the height and weight measurements). 
 
7.7 PHYSICAL EXAMINATION 
The physical examination will include r outine examinations for the following: 
 Head, Ears, Eyes, Nose, Throat (HEENT) 
 Abnormalities of the extremities 
 Neurologic abnormalities 
 Heart/cardiovascular abnormalities 
 Musculoskeletal abnormalities 
 Dermatologic  abnormalities 
 Any other body system for which an abnormality is no ted and which, in the opi[INVESTIGATOR_684], is relevant to the safety of the su bject or could impact safety or efficacy results 
for the subject; i.e., the abnorma lity is clinically significant. 
Each abnormality will be r ecorded and the Investigat or will record an assessment of it s clinical 
significance. 
The complete physical ex amination will be conduc ted at the Screening Visit (SV), T1 (Pre- 
treatment) and End of Treatment (EOT) Visit. Only symptom- directed physical examination will 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 70 of 96  
 be performed at treatment visits T2, T6, T10 and at unscheduled visits within the Treatment period 
and also at Early Termination (ET) Visit and Follow-up Visit. 
 
7.8 ELECTROCARDIOGRAM  (ECG) 
A resting supi[INVESTIGATOR_050] 12-lead ECG will be conducted at Screening Visit (SV), T1 (Pre-treatment), T2, 
T6, T10, EOT/ET visits. A 12-lead ECG will be repeated during the study only if clinically 
indicated and at the discretion of the treating physician. The results will be evaluated by [CONTACT_3786]. The following parameters will be recorded: ventricular rate (beats per minute), PR interval (msec), QRS interval (msec), QT interval (msec), and QTc interval (msec). Additionally, 
the Investigator will record the overall results of  the ECG reading as either normal or abnormal, 
and as either not clinical ly significant or clinica lly significant. If abnormal ities are observed, each 
will be recorded. 
 
7.9 CLINICAL LABORATORY ASSESSMENTS 
Blood samples will be collected for an alysis of the following parameters: 
 Hematology (Complete Blood Count) will be perform ed at SV, T1 (prior to first dose), T2, 
T6, T10, EOT/ET visits. 
 Biochemistry will be performed at SV, T1 (pri or to first dose), T2, T6, T10, EOT/ET and 
FU visits. 
Note: Screening laboratory test can be re peated once during the 28-day screening window 
based on the Investigator’s  clinical judgement). 
 Serum pro-inflammatory biomarkers includ ing IL-1 alpha, IL-1 beta, IL-6, RANTES 
(CCL5), TNF-alpha, TNF-beta, CRP will be perform ed at T1 (prior to first dose), T2 (pre- 
dose), T6 (pre-dose), T10 (pre-dose), EOT/ET and FU visits. 
 FibroTest (requires fasting for 12 hours or more) combines [ADDRESS_1073017] biomarkers (gamma- 
glutamyltransferase, total bilirubin, alpha-2-macroglobu lin, apolipoprotein A1, and 
haptoglobin). The Acti-Test adds a mark er for inflammatory activity (alanine 
aminotransferase: ALT). FibroTest will be performed at SV, T1 (prior to first dose), T2, T6, T10, EOT/ET visits. 
 Serology tests including HBs Ag, HCV Ab a nd HCV RNA (only performed if HCV Ab is 
positive), HIV Ab, Hepatitis A and Hepatitis E Abs will be performed at SV. 
 Anti-Drug antibodies (ADA) to PRO 140 at T1 (pri or to first dose), T2 (pre-dose), T6 (pre- 
dose), T10 (pre-dose), EOT/ET and FU visits. 
 PK assessment at T1 (prior to first dose), T2 (pre-dose), T6 (pre-dose), T10 (pre-dose), 
EOT/ET and FU visits. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 71 of 96  
  Serum pregnancy test (for female subj ects of childbearing potential) at SV. 
 Monocyte/T cell CCR5 biomarker assay at T1 (pri or to first dose), T2 (pre-dose), T6 (pre- 
dose), T10 (pre-dose), EOT/ET and FU visits. 
Note: In case subjects have already completed their EOT/ET and FU visits, site should use 
the Unscheduled Visit option to collect bl ood sample for Monocyte/T Cell CCR5 analysis. 
 
Urine samples will be collected for an alysis of the following parameters: 
 Urine pregnancy at T1 (prior to first dose), T6, T10, EOT/ET visits. 
Note: A urine sample will be collected from fe male subjects of childbearing potential. This 
test will be performed at the study s ite using a commercially available kit. 
 Urine analysis testing at SV, T1 (prior to first dose), T2, T6, T10, EOT/ET visits. 
Urine samples will be tested for color, appearance,  specific gravity, pH, pr otein, glucose, occult 
blood, ketones, leukocyte esterase s, nitrites, bilirubin,  urobilinogen. Micros copic examination of 
urine sediment will be performed if there are abnormalities in ma croscopic urinalysis results. 
Microscopic urine tests include  bacteria, cast, crystals, ep ithelial cells, RBC and WBC. 
All laboratory reports will be revi ewed by [CONTACT_737]. Abnormal results that are considered by 
[CONTACT_780589]. In order to make the 
determination of clinical significance the testing may be needed to be repeated as per Investigator’s 
judgement. Validated, quality-contro lled laboratory data will be tran sferred to the main database 
for analyses. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 73 of 96  
  
Total Bilirubin 0.2-0.9 mg/dl 
Direct Bilirubin 0.0 – 0.2 mg/dl 
SGOT (AST) 15-41 IU/L 
SGPT (ALT) M: 17-63 IU/L; F: 14-54 IU/L 
Alkaline Phosphatase (ALP) 34-104 IU/L 
 
Sample Collection Guidelines 
Please refer to laboratory manual for more details 
 
Sample Processing, Storage, and Shipment 
Please refer to laboratory manual for more details 
 
7.[ADDRESS_1073018]-injection 
or longer if necessary for injection si te reaction as per CTCAE v5.0. Refer to Sections 0 for more 
details. 
 
7.12 PAIN SEVERITY ASSESSMENT 
Tolerability of repeated subcut aneous administration of Leronlimab (PRO 140) is evaluated based 
on assessment of subject-perceived  injection site pain using 11- point Numeric Pain Rating Scale. 
Before each study treatment administration (T2 to T13, and at EOT), subjects will be asked to 
evaluate the pain intensity over the past week at the site of injection administration based on 11- 
point Numeric Rating Scale from 0 to 10. “0” meaning “no pain” a nd “10” meaning “worst possible 
pain”. 
Figure 7-1: 11-Point Numeric Pain Rating Scale 
 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 74 of 96  
 7.13 FIBROSCAN 
Fibroscan ultrasound measures both liver fibrosis (scarring) and steatosis (fatty change). FibroScan 
steatosis (Controlled Attenuation Parameter (CAP)) score and fibrosis score will be evaluated for 
eligibility in this study. 
 
7.14 LIVER MRI (M ULTI SCAN) 
Liver MRI (MultiScan) is a non-invasive diagnostic  technology for evaluating liver diseases using 
multiparametric MRI to non-inva sively quantify liver tissue. Combining the information from 
multiple parametric maps provides a comprehensive analysis of liver tissue, which can be used to 
aid the diagnosis of liver disorders. 
The Magnetic Resonance Imaging–derived Proton Density Fat Fraction (MRI-PDFF) is a novel 
imaging-based biomarker that allows  fat mappi[INVESTIGATOR_668988]. 
Corrected T1 (cT1) is also an MRI-based diagnosti c imaging biomarker of the liver. cT1 is intended 
to be used as a proxy for inflammation and fibrosis. 
In this study, Liver MRI will be performed to ev aluate MRI-derived biomarkers such as PDFF and 
cT1 at SV and EOT/ET visits. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 75 of 96  
 8 STATISTICAL  ANALYSIS  
 
This section presents general info rmation about statistica l considerations and concepts and a brief 
discussion on analysis methodology, as well as some data conventions. Detailed descriptions of the 
statistical analysis methods and data conventions that  will be used in this study will be in a separate 
document; i.e., the Statistical Analysis Plan (SAP). 
 
8.1 TREATMENT GROUPS 
 
In Part 1 of the study, all el igible subjects will be randomized to receive PRO 140 as a 700mg 
subcutaneous injection or placebo weekly for up to 13 weeks. 
In Part 2 of the study, all eligib le subjects will receive PRO 140 as a 350 mg subcutaneous injection 
weekly for up to 13 weeks. 
 
8.2 STUDY OUTCOME MEASURES 
 
Primary Efficacy Outcome Measure: 
 Change from baseline in hepatic fat fracti on assessed by [CONTACT_9252]- 
derived proton density fat fract ion (MRI-PDFF) at week 14 
 Secondary Efficacy Outcome Measures: 
 Change from baseline in fibro-inflammatory ac tivity as assessed by [CONTACT_780590]1 (corrected T1) 
assessed by [CONTACT_780591] (MRI) of li ver at week 14 
Note: cT1 measured in milliseconds (ms) is a quantitative metric for assessing a composite 
of liver inflammation and fibrosis 
 Change from baseline in liver fibros is using FibroTest at week 14 
 Change from baseline in hepa tic inflammatory activity using FibroTest at week 14 
 Change from baseline in serum pro-in flammatory biomarkers assessments 
 Change from baseline in Gamma-glutam yltransferase (GGT) at week 14 
 Change from baseline in CK-18 level at week 14 
 Change from baseline in Leronlim ab (PRO 140) PK assessments 
Exploratory Outcome Measures: 
 Change from baseline in Alanine tr ansaminase (ALT) at week 14 
 Change from baseline in Aspartate transaminase (AST) at week 14 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 76 of 96  
  Change from baseline in total bilirubin at week 14 
 Change from baseline in triglycerides at week 14 
 Change from baseline in Low Density Lipoprotein (LDL) at week 14 
 To explore Monocyte/T cell CCR5 biomarkers that may predict activity of leronlimab. 
 
8.3 SAMPLE SIZE DETERMINATION AND RATIONALE 
 
The sample size of 90 total subjects [60 subjects (30 subjects per arm) for the Randomized Phase 
and up to 30 subjects for the non-randomized, open-lab el phase] is selected on the basis of clinical 
judgment and not based on statistical power calculation. The number of subjects is deemed adequate to provide clinically meaningful descriptiv e results consistent with study objectives. 
 
8.4 RANDOMIZATION 
Subjects who are eligible to participate in the trial will be randomized to one of the treatment groups 
via IWRS (Interactive Web Based Randomization System) at the T1 Visit prior to IP administration. The randomization will be central and will us e 1:1 ratio of Treatment groups A and B: 
 PRO 140 700mg SC weekly injection (Group A) 
 Placebo 0 mg SC weekly injection (Group B) 
Note: Randomization is not applicable for the open-label, single-arm portion (Part 2) of the study. 
 
8.5 BLINDING 
All subjects, Investigators and their staff, and all Sponsor/ CRO personnel involved in the 
management of the study will be blinded to treatment assignments. 
The Information Technology department w ill be unblinded to treatment. As noted above, 
the  Technology department is not otherwise involved with the study. 
Treatment unblinding for the study will occur after all clinical data have  been received, data 
inconsistencies have been resolved, and the databa se is locked, except for safety reasons on a case- 
by-case basis (i.e., emergency unblinding). 
Note: Blinding is not applicable for the open-la bel, single-arm portion (Part 2) of the study. 
 
8.6 INTERIM ANALYSIS 
No interim analysis (IA) will be performed for effi cacy. 
 
8.7 GENERAL STATISTICAL CONSIDERATIONS 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1073019] data listings . Statistical analyses will be 
performed using SAS® for Windows, version 9.4 or later. Desc riptive statistics (n, mean, standard 
deviation, median, minimum and maximum) will be presented by [CONTACT_780592]. Frequencies and percentages will be  presented by [CONTACT_11566]. 
Analysis Populations 
Intent-to-Treat  Population  
The Intent-to-Treat (ITT) population is defined as the set of subjec ts who have received at least 
one dose of study treatment (Leronlimab (PRO 140) or placebo) and have at least one post-baseline 
efficacy assessment. The ITT population will be used as the primary analysis population. 
Per Protocol Population 
The Per Protocol (PP) population is defined as the set of subjects who meet the ITT population 
requirements, were not associated with any major protocol violations and have at least 80% of 
compliance with study treatment. This population w ill be identified before the database lock. 
The PP analysis of primary and secondary endpoints will be considered su pportive. 
 
Safety Population 
The Safety Population will include all subjects who have received one dose of study treatment 
(Leronlimab (PRO 140) or placebo). This population will be used for the analysis of safety 
parameters. 
Covariates 
For efficacy analyses, the baseline values will be us ed as covariates in the analysis models. Other 
important prognostic factors will be specified in the SAP for the study. 
Missing Data 
All data will be used as observed, and no imputations will be made for any missing data point for 
early phase study. 
 
8.[ADDRESS_1073020] with a Type I error rate of 0.05. 
All the efficacy analyses  presented here will be conducted using both the ITT and PP populations. 
All safety analyses wi ll be conducted using the Safety populat ion. Continuous data summaries w ill 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1073021]-enrollment discontinuations will be listed and/or summ arized by [CONTACT_6490]. 
Demographic and Baseline Disease Characteristics 
Demographics and baseline disease characteristics including medical history, prior and concomitant 
medications/therapi[INVESTIGATOR_780577]/or su mmarized by [CONTACT_696002]. 
Study Analyses 
Efficacy Analysis 
Analysis of the efficacy endpoints will be conducted according to below met hods: 
o If the Normality assumption is met, Anal ysis of Covariance (ANCOVA) or Mixed 
Model using the covariates in the model. 
o If the Normality assumption is not met,  a non-parametric method or a rank – 
ANCOVA analysis will be used. 
Safety Analyses 
Safety will be assessed by [CONTACT_780593] e monitoring and timely assessment of adverse events (AEs), 
laboratory parameters (blood tests,  urinalysis), vital si gns (blood pressure, h eart rate), subject’s 
medical condition (physical examinat ion including weight). Tolerability of repeated subcutaneous 
administration of Leronlimab (PRO 140) as assessed by [CONTACT_19288] (using 11-point Numeric 
Pain Rating Scale) and by [CONTACT_1697]-e valuation of injection site reactions. 
 
Adverse Events 
Adverse events will be coded using the most recent version of Medical Dictionary for Regulatory 
Activities (MedDRA). Treatment Em ergent AE’s (TEAE) are defined as events with an onset on 
or after the first treat ment. TEAEs will be summarized by [CONTACT_64240], System Organ Class, 
and preferred term. The following TE AE summaries will be provided: 
 by [CONTACT_780594] 
 by [CONTACT_3592] 
 by [CONTACT_2946], PT, and severity 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 79 of 96  
  by [CONTACT_2946], PT, and relationship to study drug 
 
Clinical Laboratory Data 
All laboratory values will be listed. Laboratory measurements will also be summarized as 
continuous variable and presented by [CONTACT_11571]. 
 
Physical Examination 
All physical examination findings will be listed and/or summarized. 
 
Vital Signs 
All vital sign findings will be listed and summarized. 
Electrocardiograms (ECGs) 
All ECG findings will be listed and summarized. 
Tolerability 
Pain severity assessment (using 11-point Numeric Pain Rating Scale) and injection site reactions 
will be listed and summarized. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 80 of 96  
 9 ADVERSE EVENTS (DEFINIT IONS AND REPORTING) 
 
The Investigator is responsible for the detection and documentation of events meeting the criteria 
and definition of an AE or SAE, as provided in this protocol. During the study when there is a safety 
evaluation, the Investigator or site staff will be responsible for detecting, documenting and reporting 
AEs and SAEs as detailed in this Section of the protocol. 
 
9.1 ADVERSE EVENT (AE) 
An adverse event (AE) is defined as any unfavorab le or unintended sign, sy mptom, or disease that 
occurs or is reported by [CONTACT_780595] o ccurred, or a worsening of  a pre-existing condition. 
An adverse event may or may not be  related to the study treatment. 
AEs will be elicited through dire ct questioning and subject reports. Any abnormalities in visit 
evaluations, physical examination fi ndings or laboratory results that the investigator believes are 
clinically significant to the research subject and that occurred after initiation of the first study 
treatment will be repor ted as AEs. Abnormal findings that ar e NOT clinically significant should be 
not be recorded as an AE. 
 
9.2 REPORTING AND FOLLOW -UP OF ADVERSE EVENTS 
Report initiation for all AEs and seri ous adverse events (SAEs), (see Section 9.3), will begin at the 
time of the first treatment and continue up to the final st udy visit. All events will be followed to 
resolution or until [ADDRESS_1073022]’s medi cal records and on the CRF. AEs will be reported 
using customary medical terminology along with the following information: the onset and end dates, whether the event is considered to be a SAE (see Section 9.3), the impact the event had on 
study treatment (see Section 0 ), the CTCAE grade (intensity) of the event (see Section 0 ), the 
causality of the event (see Section 0 ), whether treatment was given as a result of the event (see 
Section 0 ), and the outcome of the event (see Section 0 ). 
Impact on Study Treatment 
The impact the event had on the study treatment w ill be assessed as either: dose increased, dose not 
changed, dose reduced, drug interrupted, drug w ithdrawn, unknown, and not applicable. The “not 
applicable” assessment will be used only when th e subject is no longer in the treatment period of 
the protocol or died. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 82 of 96  
 4. Probably – The event follows a reasonable tempor al sequence from th e study biologic or 
control, abates upon discontinuati on of the study drug or control,  or cannot be reasonably 
explained by [CONTACT_780596]’s clinical state. 
5. Definitely – The event follows a reasonable tempor al sequence from the study biologic or 
control, abates upon discontinuation and cannot be explaine d by [CONTACT_431104]’s clinical state. 
Treatment Given as a Result of the Event 
The event impact in terms of treatment provided  will be as either: none, medication administered, 
non-drug therapy administered, surg ery performed, hospi[INVESTIGATOR_059], or other (with a specification). 
Outcome Assessment 
The outcome of the event will be assessed as either: fatal, not recovered/not resolved, 
recovered/resolved, recovered/resolved with sequalae, recovering/resolving, and unknown. Only 
one AE per subject is allowed to have an outcome  assessment as “death.” If there are multiple 
causes of death for a given subject, only the primary cause of death will have an outcome of death 
Injection-site reactions 
Injection-site reactions thought to be directly related to the inject ion are considered to be AEs of 
special interest, and will be assessed as per CTCAE v5.0. 
For subjects who develop Grade [ADDRESS_1073023] be notified.  
For Grade 4 events permanently discontinue therapy. 
 
9.3 SERIOUS ADVERSE EVENTS 
A SAE is defined as any AE that: 
 Results in death 
 Is life threatening (the subject is at immedi ate risk of dying from the adverse experience) 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 83 of 96  
  Requires subject hospi[INVESTIGATOR_187227] 
 Results in persistent or si gnificant disability/incapacity 
 Is a congenital anomaly/birth defect 
 Important medical events that may not result in death, be life-threatening, or require 
hospi[INVESTIGATOR_3767]  a serious adverse device eff ect when, based upon appropriate 
medical judgment, they may jeopardize the su bject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition 
 
9.4 REPORTING OF SERIOUS ADVERSE EVENTS 
The Investigator is required to report all SAEs  that occur during the time period specified in 
Section 9.2 . Once the Investigator becomes aware of an  SAE, he/she must report the SAE to 
 Safety and Pharmacovigila nce Department within 24 hours: 
 
 
 
 
A written SAE report must include a full desc ription of the event as described in Section 9.[ADDRESS_1073024] addi tional supporting documentation as it becomes available, such 
as lab reports, electrocardiogr am (ECG) reports, discharge summary, hospi[INVESTIGATOR_11533], etc, if 
applicable. 
The Investigator is also responsible for reporting all SAEs to the appropriate Institutional Review 
Board (IRB) in accordance with local laws and regu lations. The Investigator is responsible for 
maintaining documentation in the study file that  indicates the IRB has been properly notified. 
 
9.[ADDRESS_1073025] be closely followed 
until sufficient information is obtained to indica te a return to normal status or until the event 
stabilizes at a level acceptable to the investigator (i.e., recovery, retu rn to baseline status, no further 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 84 of 96  
 improvement expected, or death). 
For each SAE indicated as an unresolved event on the initial report, rega rdless of whether the 
subject completed the study or w ithdrew, the site should submit a follow-up report with updated 
information. 
9.5.1.  Regulatory Reporting Requirements for SAEs 
The investigator, or responsible person per local requi rements, must comply w ith the applicable local 
regulatory requirements related to the reports of SAEs to regulatory authorities and the Institutional 
Review Board (IRB)/ Institutional Ethics Committee (IEC). 
The Sponsor is responsible for the ongoing evalua tion of the study drug. Any adverse experience 
associated with the use of the study drug that is both se rious and unexpected must be reported. In 
accordance with the US Code of Federal Regul ations, Title [ADDRESS_1073026] submit written documentation in the form of an  Investigational New Drug (IND) 
Safety Report or suspected unexpected serious a dverse reaction (S[LOCATION_003]R) reports, respectively. All 
events qualifying as IND Safety Reports/SUS ARs will be reported to the IRB/IECs, and 
Investigators will be provided by [CONTACT_780597]. IND Safety 
Reports/S[LOCATION_003]Rs are required to be reported within [ADDRESS_1073027] 
notification of the IND Safety Reports/S[LOCATION_003]Rs to the drug safety group from the Investigator. 
The Sponsor should submit to the regulatory author ity all safety updates and periodic reports, as 
required by [CONTACT_25435]. 
 
9.[ADDRESS_1073028] be re ported to Medical Monitor within the same 
timelines as an SAE usin g the appropriate form. The outcome of  a pregnancy should be followed up 
carefully and any abnormal outcome of the mother a nd/or child should be reported. The investigator 
must report any pregnancy that occurs in a study subject. Any female subject who becomes pregnant 
during the study will be discontin ued from investigational product and will be followed for 
pregnancy outcome. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1073029] ACCESS TO SOURCE  DATA/DOCUMENTATION 
 
Subjects will be identified on eCRFs by a unique subject identification number and on source 
documents by [CONTACT_11572]. No personal identifier will be used in any publication or communication used to support this research study.  The subject identification number will be used 
if it becomes necessary to identify  data specific to a single subject. 
The local IRB, FDA, the monitors, auditors and pe rsonnel authorized by [CONTACT_941] S ponsor are eligible to 
review the medical and research reco rds related to this study as part of their responsibility to protect 
human subjects in clinical research. They wi ll be given direct acce ss to source data and 
documentation (e.g., medical charts/records, print outs etc.) for source data  verification, provided 
that subject confidentiality is maintained in accordance with local requirements. Access to 
electronic medical records may be governed by [CONTACT_780598]. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 86 of 96  
 11 QUALITY  CONTROL  AND  QUALITY  ASSURANCE  
 
11.1 MONITORING REQUIREMENTS 
The specific obligations outlined in 21 Code of Federal Regulat ions (CFR) and ICH guidelines 
require the Sponsor to maintain current personal knowledge of the progress of a study. Therefore, 
the Sponsor's designated monitor will visit the site during the study as well as maintain frequent 
telephone and written communication. The Investigator will permit the Sponsor to monitor the study as frequently as is deemed necessary and pr ovide access to medical re cords to ensure that 
data are being recorded adequately, that data are verifiable and that protocol adherence is 
satisfactory. 
As delineated above, the Investigator will permit representatives of the S ponsor and/or designated 
CRO to inspect all CRFs and corresponding study subject original medical records (source 
documents) at regular intervals throughout the study. Subject orig inal medical records and other 
relevant data must be available to support all data recorded in the eCRF. In addition to the original 
medical records, these data may include but are not limited to study, laboratory reports, etc. 
In accordance with federal regulations, site inspectio ns will serve to verify strict adherence to the 
protocol and the accuracy of the data that is bein g entered on the case report forms. A Monitoring 
Log will be maintained at each study site. The M onitoring Log will be signed by [CONTACT_2037], dated 
and stated the type of vi sit. The Investigator should be aware th at the study site and subject records 
may be inspected by [CONTACT_780599], FDA or other 
regional regulatory authority. 
 
11.2 ACCEPTABILITY OF CASE REPORT FORMS (CRF S) 
For each subject who has signed an informed consen t form, a CRF must be completed. For subjects 
who are screen failures, this woul d be limited to the screen failur e CRF page. All source documents 
and CRFs will be completed as soon  as possible after the subject's visit and corrections to data on 
the CRFs will be documented, if applicable. The I nvestigator will review the CRFs to indicate that, 
to his/her knowledge, they are complete and accu rate. CRFs will be reviewed by [CONTACT_1034]’s or 
designated CRO’s monitor, who will make  a decision as to their acceptability. 
 
11.[ADDRESS_1073030] obtaining  the concurrence of the 
Sponsor. Approval by [CONTACT_12244] r’s IRB must also be obtained prior to implementation of the 
change, with two exceptions: 
1. When necessary to eliminate apparent  immediate hazard to the subject; or 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1073031]’s participation in the trial. 
An amendment may also require mo dification of the informed consent form. The Investigator will 
provide an approval letter for th e amendment and revised informed consent form, if applicable, to 
the Sponsor. An amendment must be provided in writing and it must be da ted by [CONTACT_509967]. If necessary, the Sponsor will submit pr otocol amendments to FDA and other 
appropriate regulatory authorities and notify other Investigators us ing this protocol. 
 
11.[ADDRESS_1073032]'s rights, safety, or well being a nd/or the completeness, accuracy and reliability of 
the study data. Examples of this include: 
 Failure to obtain informed consent prior to initiation of study- related procedures 
 A research subject does not meet  the protocol's eligibility cr iteria but was enrolled without 
prior approval from the sponsor. 
 A research subject received the wr ong treatment or incorrect dose. 
 A research subject met withdrawal criter ia during the study but was not withdrawn. 
 A research subject received a prohibited concomitant medication. 
 Failure to treat research subjec ts per protocol procedures that specifically relate to primary 
efficacy outcomes. 
 Changing the protocol without pr ior sponsor and IRB approval. 
 Multiple minor violations of the same nature after multiple warnings. 
 Minor Protocol Deviation or Violation 
A minor protocol deviation is any change, divergence, or de parture from the study design or 
procedures of a research protocol that has not been approved by [CONTACT_3433] e IRB and which DOES NOT 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1073033]'s rights, safety or well-being, or the completeness, accuracy and 
reliability of the study data. Examples of this include: 
 Follow-up visits that occurred outside the pr otocol required time frame because of the 
participant’s schedule. 
 Blood samples obtained at times close to but not precisely at the time points specified in the 
protocol. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 89 of 96  
 12 ETHICS  AND  REGULATORY  REQUIREMENTS  
 
This study is to be conducted in accordance with  the specifications of this protocol and in 
accordance with principles consistent with Declar ation of Helsinki, GCP, 21 CFR, ICH E6, HIPAA 
regulations in 45 CFR Part 164 (US only), and the Belmont Principles of respect for persons, 
beneficence, and justice. No protocol changes w ill be implemented without the prior review and 
approval of the IRB, except when the modification does not involve the subject’s participation in 
the trial or where it may be necessary to eliminate an immediate hazard to a research subject. In the 
latter case, the change will be reported to the IRB as soon as possible, according to IRB regulations. 
Additionally, the study product used in this study is manufactured, handled and stored in accordance 
with applicable GMP. The study product provided for this study will be used only in accordance with this protocol. 
 
12.[ADDRESS_1073034] /INDEPENDENT  ETHICS  COMMITTEE  (IRB/IEC)  
The Principal Investigator (PI) at the site will provide the Institutional Review Board/Independent 
Ethics Committee (IRB/IEC) with all appropriate materials as required by [CONTACT_11577]/IEC, including 
but not limited to the clinical st udy protocol, informed consent form , and any advertising materials. 
The study will not be initiated until the IRB/IEC provides written approval of the aforementioned documents and until approval docu ments have been obtained by [CONTACT_3433] e Principal Investigator [INVESTIGATOR_520833]. Th e Investigator will not partic ipate in the decision. If the 
Investigator is an IRB or IEC member, documen tation must be provided indicating recusal from 
the approval process. Appropriate reports on the progress of this st udy by [CONTACT_079] 
[INVESTIGATOR_26458]/IEC as required by [CONTACT_714242]. The Investigator is required to maintain an accurate and complete record of all written correspondence to and received from the IRB/IEC, and 
must agree to share all such documents and reports with the Sponsor. 
No changes from the final approved  protocol will be in itiated without the IRB/IEC’s prior written 
approval or favorable opi[INVESTIGATOR_1101] a written ame ndment, except when necessary to eliminate 
immediate hazards to the subjects or when the modification does not involve the subject’s 
participation in the trial. 
 
12.2 INVESTIGATOR ’S RESPONSIBILITIES 
The Investigators are responsible for performing the study in full accordance with the protocol and 
the current revision of the Declaration of Hels inki, the Good Clinical Practice: Consolidated 
Guideline, approved by [CONTACT_11580], and any applicable national and local laws and regulations. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1073035] INFORMED CONSENT REQUIREMENTS 
All subjects participating in this study will be given to by [CONTACT_11219]/or designee, written 
and oral information about the study in a language unders tandable by [CONTACT_423]. Written informed 
consent will be obtained from each subject prior any procedures or asse ssments that would not 
otherwise be required for the care of the subject are done and after the ai ms, methods, anticipated 
benefits, potential hazards, and in surance arrangements in force are explained and the subject has 
been given sufficient time to ask questions and cons ider participation in the study. It will also be 
explained to the subjects that they are free to re fuse entry into the study and free to withdraw from 
the study at any time without prejudi ce to future treatment. It is perm issible for a third person (e.g., 
a family member) to be present du ring the explanation of the study. 
The written Informed Consent Form ICF will be  in compliance with CFR 21 Part 50.27 and GCP 
guidelines. The Sponsor and/or designated CRO will approve the ICF and all amendments to the 
ICF prior to submission to the IRB/IEC. A copy of the ICF to be used will be submitted by [CONTACT_26492]/IEC for review and approva l prior to the start of the study. The study site 
must provide the Sponsor with an unsigned copy  of IRB/IEC-approved ICF along with applicable 
documentation to support this appr oval. The original signed ICF is retained in the subject's study 
records, and a copy is provided to  the subject. A second copy may be filed in the subject’s medical 
record, if allowed by [CONTACT_10569]. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-[ADDRESS_1073036]'s medical record. If separate research 
records are maintained by [CONTACT_737](s), the medical record and the research records will be 
considered the source documents for the purposes of auditing the study. 
Applicable source data will be manually transc ribed to approve case report forms (CRF). The 
Investigator is ultimately responsible for the accuracy of the data transcribed on the forms. All source documents and CRFs will be completed as soon as possible after the subject's visit. 
The Investigator will review the CRFs to indicate that, to his/he r knowledge, they are complete and 
accurate. Designated source documents will be signed  and dated by [CONTACT_26493]. 
The Investigator must agree to complete and ma intain source documents and CRFs for each subject 
participating in the study. 
All research data will be entered, either electroni cally or manually, into a computerized database. 
The clinical database will be designed by [CONTACT_780600] [ADDRESS_1073037]’s 
study number, name, date of birth,  and unique hospi[INVESTIGATOR_11538]. This list 
will be kept by [CONTACT_26494]. A notation will be made 
in the subject’s case history/medical chart that he /she is participating in  a clinical study and has 
provided a signed and dated ICF as well as a release for protected health information as required 
by [CONTACT_11582]. The Investigator must also mainta in a separate screening log of all the subjects 
screened for participation in the study; it should  include gender, age, eligibility status, reason for 
ineligibility, if applicable; and study a llocated subject number, if applicable. 
 
13.2 CLINICAL DATA MANAGEMENT 
The Sponsor and/or designated CRO will be responsible for the processing and quality control of 
the data. Data management will be carried out as described in the Sponsor’s or CRO’s standard 
operating procedures (SOPs) for clinical studies. 
The handling of data, including data quality c ontrol, will comply with regulatory guidelines 
(e.g., ICH E6 GCP, and local regulations where applicab le) and the Sponsor’s or the CRO’s SOPs 
as well as provisions of the study- specific Data Management Plan. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 92 of 96  
 13.3 ARCHIVING 
All study documentation at the Inve stigator site and Sponsor site  will be archived in accordance 
with ICH GCP E6 and the Sponsor ’s quality standards and SOPs. 
The Investigator will maintain all research records,  reports, and cas e history reports for a period of 
two (2) years after regulatory approv al of the investigational product. If no application is filed or if 
the application is not approved, r ecords must be maintained for two (2) years after all investigations 
have been completed, terminated or di scontinued and the FDA has been notified. 
These documents should be retained for a longer period however, if requi red by [CONTACT_780601] (as per 
GCP 5.5.11). 
At the completion of the study, details of the archival process must be provided to the Sponsor. 
Study records are subject to inspection by [CONTACT_780602]. 
Records to be retained by [CONTACT_780603], but are not restricted to: 
 Source data and the primary records upon which they are based (e.g., subject’s progress 
notes, adverse event data, test results, and any other diagnostic procedures required to 
evaluate the progress of the study) 
 Completed CRFs 
 Signed protocols and protocol amendments 
 Laboratory results, ranges, and certifications 
 IP and accountability records 
 Study personnel signature [CONTACT_26500] 
 Monitoring logs 
 Correspondence to and from the Sponsor, designee and IRB 
 Investigator and sub-investigator CVs 
 Signed informed consent and protected health information consent forms 
 Subject screening 
 SAE reports 
 IRB approval and re-approval letters 
 Other documents pertaining to the conduct of the study 
These documents must be maintained  and kept on file by [CONTACT_780604]. 
Study records should not be transferred from site or destroyed without prior written agreement 
between the Sponsor and the study Investigator . Study records are subject to inspection by 
[CONTACT_780605]. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 93 of 96  
 14 PUBLICATION  PLAN 
 
All information supplied by [CONTACT_780606] n in connection with this study and not previously published, 
is considered confidential information. This in formation includes, but is not limited to, the 
Investigator’s Brochure, clinical protocol, case report forms and other scientific data. Any data 
collected during the study are also considered confidential. This confidential information shall 
remain the sole property of CytoDyn, shall not be  disclosed to others without the written consent 
of CytoDyn, and shall not be used ex cept in the performance of this study. 
It is understood by [CONTACT_780607]. Therefore, this info rmation may be disclosed 
as required to other Investigators or appropriate regulat ory authorities. By [CONTACT_780608], the Inves tigator understands that he/she has an obligation to provide the Sponsor 
with complete test results and all data developed during this trial. 
Publication and Disclosure : The site and Investigator agree to submit any proposed manuscript, 
presentation or other public disclosu re regarding the study to Sponsor fo r review at least thirty (30) 
days prior to submitting such proposed manuscript to a publisher or delivering or making such 
presentation or other public disclo sure to any third party. Within th irty (30) days of its receipt, 
Sponsor shall advise the site and/or Investigator , as the case may be, in writing of any information 
contained therein that is confiden tial information (other than resear ch results included in a proposed 
manuscript) or that may impair S ponsor’s ability to obtain patent pr otection. Sponsor shall have the 
right to require the site and/or  Investigator, as applicable, to remove specifically identified 
confidential information (but ma y not require removal of research results from a proposed 
manuscript) and/or to delay the proposed submission or delivery  of the proposed manuscript or 
presentation, or other public disclosure, for an add itional sixty (60) days to enable Sponsor to seek 
patent protection. The site and Investigator shall not publish, publicly disclose, present or discuss any results of or information pertai ning to the site’s and Investigat or’s activities prior to completion 
of the trial, even if the multi- center trial or the study is termin ated before its completion and the 
final clinical study report is signed off, or with respect to any endpoints or analyses other than those 
specified in this protocol. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 94 of 96  
 15 REFERENCES 
 
Cichoż -Lach, H., Celi ński, K., Prozorow-Król, B., Swatek, J., S łomka, M., & Lach, T. (2012). The 
BARD score and the NAFLD fibrosis score in th e assessment of advanced liver fibrosis in 
nonalcoholic fatty liver disease. Med Sci Monit, 18(12), CR735–CR740. 
Jacobson JM, Saag MS, Thompson MA, Fischl MA , Liporace R, Reichman RC, Redfield RR, 
Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD . Antiviral activity of single-dose PRO 140, a 
CCR5 monoclonal antibody, in HI V-infected adults. Journal of  Infectious Diseases. 2008 Nov 
1;198(9):1345-52. 
 
Jack X. Q. Pang. Liver Stiffness by [CONTACT_780609]-Related Complications 
and Mortality in Patients with Chronic Liver Disease. PLoS One, 2014; 9(4). 
Manca Povsic, L. O. A structured literature revi ew of interventions used in the management of 
nonalcoholic steatohepatitis (NASH). Phar macol Res Perspect, 2019; 7(3), e00485. 
Naga Chalasani, Z. Y. The Diagnosis a nd Management of Nonalcoholic Fatty Liver 
Disease:Practice Guidance From the American Association for the Study of Liver Diseases. 
HEPATOLOGY, 2018; 67(1) 
Lefebvre E, M. G. Antifibrotic Effects of th e Dual CCR2/CCR5 Antagonist Cenicriviroc in 
Animal Models of Liver and Ki dney Fibrosis. 2016; 11(6), e0158156 
Suleiman J, Zingman BS, Diaz RS, Ramalho Madr uga JV, DeJesus E, Slim J, Mak C, Lee E, 
McCarthy MC, Dunkle LM, Walmsley S. Vicriviroc in combination thera py with an optimized 
regimen for treatment-experienced subjects: 48-week results of th e VICTOR-E1 phase 2 trial. The 
Journal of infectious diseases. 2010 Feb 15;201(4):590-9. 
Thompson M, Lalezari J, Saag M, Jacobson J, Zingman B, Stambler N, D'Ambrosio P, Maddon P, 
Olson W, Morris S. Weekly and biweekly subcut aneous PRO 140 demonstrates potent, sustained 
antiviral activity. In16th Conference on Retroviru ses and Opportunistic Inf ections 2009 Feb 8 (pp. 
8-11). 
US Food and Drug Administration. Noncirrhotic  Nonalcoholic Steatohepatitis With Liver 
Fibrosis:Developi[INVESTIGATOR_780578]. December 2018. 37256dft.docx 
Zobair M. Younossi, F. The epi[INVESTIGATOR_780579]. Clin Liver Dis 
(Hoboken), 2018; 11(4), 92–94. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 95 of 96  
 16 APPENDIX 
 
16.1 APPENDIX 1: A CCEPTABLE METHODS OF CONTRACEPTION 
 
 
 
Barrier Methods Intrauterine Device Methods Hormonal Methods 
 Male condom plus 
spermicide 
 Cap plus spermicide 
 Diaphragm plus spermicide  Copper T 
 Progesterone T 
 
Levonorgestrel- releasing  Implants 
 Hormone shot or injection 
 Combined pi[INVESTIGATOR_4382] 
 Minipi[INVESTIGATOR_4382] 
 Patch 
NOTE: choice of contraception should be discusse d with primary treating physician to discuss 
the risks and benefits of differe nt modalities of contraception. 
Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL Page 96 of 96  
  
16.2 APPENDIX 2: C OMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS V 5.0 
 
 
For complete detailed information please refer to the link below: 
https://ctep.cancer.gov/protocol Development/electronic_applica tions/docs/CTCAE_v5_Quick_Re 
ference_8.5x11.pdf  